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ABSTRACT

'COMPLEMENTARY' IMMUNE EVASION BY ORAL PATHOGEN
PORPHYROMONAS GINGIVALIS

Jennifer Lynn Krauss
November 18,2010

Complement, an early recognition system of innate immunity that senses local
tissue damage and infection, cross-talks with and regulates other signaling systems,
including Toll-like receptor (TLR) pathways. In the context of periodontitis, destructive
inflammation and disease promotion are associated with extensive and synergistic
activation of TLRs and complement within the chronically inflamed periodontium. The
virulence of the periodontal pathogen Porphyromonas gingivalis is dependent, at least in
part, upon its ability to use sophisticated stealth and sabotage tactics to undermine innate
immunity.

Intriguingly, although this pathogen can modulate TLR2 signaling and

suppress specific aspects of complement activation (126), it proactively generates an
active complement fragment (C5a) through limited degradation of the fifth complement
component (C5) by virtue of its C5 convertase-like activity.

We hypothesized that this

seemingly counterproductive action may provide a survival advantage; permitting P.
gingiva lis to instigate a subversive crosstalk between TLR2 and C5aR.

Our work

supports this hypothesis by demonstrating that C5a exposure promoted a synergistic rise
of intracellular cAMP and impaired the ability of macrophages to destroy P. gingivalis.
The cAMP synergy strictly required TLR2 signaling and a pertussis toxin- and
vii
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thapsigargin-sensitive C5a receptor pathway, whereas protein kinase A and glycogen
synthase

kinase-3~

acted as downstream effectors. Antagonistic blockade of the C5a

receptor abrogated this evasive strategy and may thus have important therapeutic
implications in treating periodontal disease. This first demonstration of complementTLR crosstalk for immunosuppressive cAMP signaling indicates that pathogens may not
simply undermine complement and/or TLRs as separate entities, but may also exploit
their crosstalk pathways.
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CHAPTER ONE: INTRODUCTION

Innate immunity: its role in periodontal disease

Innate immunity is a phylogenetically ancient system of host defense and
represents the inherited resistance to infection (70). Until relatively recently, the innate
immune response was viewed as a non-specific and temporary expedient to "buy time"
until the activation of adaptive immunity, which comprises the system of B and T
lymphocytes, each of which expresses antigen receptors of exquisite specificity (34).
Although lacking the ability to make such fine structural distinctions, innate immunity is
nevertheless endowed with considerable specificity. Indeed, germ-line encoded receptors
(collectively known as pattern-recognition receptors) can detect and respond to conserved
and generally distinct microbial structures, which are shared by related groups of
microorganisms (e.g., lipopolysaccharide of gram-negative bacteria or lipoteichoic acid
of gram-positive bacteria) (104). Most importantly, innate immunity is sophisticated
enough to make judgments that instruct the initiation and progression of the adaptive
immune response (34) (104).

In this regard, the acquired specificity of the antigen

receptors is not the result of co-evolution with microbes but the outcome of randomly
generated gene recombination. Thus, even though the adaptive immune receptors can
bind virtually any structure, they have no clue on the biological context of the
encountered antigen (i.e., should they respond or not?). This information, however, is
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provided by innate immune mechanisms, which act as mediators between detection of
infection and induction of the adaptive response. Not surprisingly, successful pathogens
which disarm or subvert host defenses target preferentially innate immunity (36) and
particularly central systems such as the complement and the Toll-like receptor (TLR)
family ofpattem-recognition receptors (88) (137).
In the oral cavity, innate immunity contributes significantly to antimicrobial
defense, although inadequate or overexuberant activation of the innate response may lead
to oral disease, such as periodontitis (32) (37).

In this context, periodontal health

represents a dynamic state where pro-inflammatory and antimicrobial activities to control
infection are optimally balanced by anti-inflammatory mechanisms to prevent
unwarranted inflammation (37). This homeostatic balance may be disrupted, however,
either by genetic defects in host immunity or by pathogens that undermine host defense
mechanisms (37) (79) (83).

It should be noted that pathogen-instigated immune

suppreSSIOn of specific pathways and destructive inflammatory responses in the
periodontium are not necessarily mutually exclusive, since the latter may arise as a
consequence of the inability to control infection (49).
The ability of periodontal pathogens to persist and establish chronic infections
suggests that they may have evolved ways to disarm these defense mechanisms or
subvert them to their advantage. Understanding the mechanisms of periodontal hostpathogen interplay can offer important insights into the disease pathogenesis and
facilitate the rational design of therapeutic interventions.

2
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Complement and TLRs: a potential for crosstalk

The term "complement" was coined by Paul Ehrlich in the late 1890s to describe a
heat-sensitive activity in serum that is complementary to that of antibody in causing lysis
of bacteria (142).

In line with this early view, the complement system has been

traditionally considered as an antimicrobial enzyme system found

In

serum and

inflammatory exudates like the gingival crevicular fluid (4) (109) (122). However, it is
now well appreciated that complement constitutes a fundamental component of innate
immunity, by virtue of its ability to orchestrate critical events during immune and
inflammatory responses, including regulation of other innate or adaptive immune
pathways (63) (90) (99) (165).
The triggering of the complement system involves sequential activation and
proteolytic cleavage of a series of serum proteins, leading to recruitment and activation of
inflammatory cells, microbial opsonization and phagocytosis, and direct lysis of targeted
pathogens (99). In addition to the serum components, the integrated complement system
also includes membrane-bound regulators and receptors for interactions with various
mediators of the immune system. Complement activation can proceed through three
distinct mechanisms, namely the classical, lectin, or alternative pathways (99) (Fig. 1).
All three pathways converge at a central step, involving activation of the third component
of complement (C3) by pathway-specific C3 convertases (87) (99). Activation of the
classical pathway is initiated by antigen-antibody complexes, whereas the lectin pathway
is triggered through interaction of a secreted pattern-recognition receptor (the mannose-
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binding lectin) with specific carbohydrate groups found on the surface of a variety of
microorganisms.

To ensure fast and immediate response to invading pathogens, the

complement cascade is maintained at a low level of activity ("tick-over") by the so-called
alternative pathway.

This pathway is initiated by spontaneous hydrolysis of C3 to

C3(H20), thereby inducing a conformational change that allows binding to complement
factor B and formation of the initial alternative pathway C3 convertase. This results in
rapid tum-over of the alternative pathway, as long as there is no sufficient negative
regulation as normally occurs with non-self surfaces (e.g., bacteria). In addition to this
mechanism, the alternative pathway can be induced by bacterial lipopolysacharide and
lipooligosacharide molecules in a way that strictly requires the participation of the plasma
protein properdin (77). The alternative pathway may represent up to 80% of complement
activation (99).

In all three pathways, proteolytic cleavage of a series of proteins

downstream of C3 leads to the generation of effector molecules, including opsonins (C3b,
iC3b) and anaphylatoxins (C3a, CSa).

The iC3b fragment is generated by further

cleavage of microbe-attached C3b and mediates phagocytosis by complement receptor-3
(Fig. 1). The inflammatory anaphylatoxins C3a and CSa activate seven-transmembrane
domain G-protein-coupled receptors, known as the C3a receptor and CSa receptor
(CD88), respectively. A newly identified but modestly characterized alternative receptor
for CSa is the so-called CSa receptor-like 2 (CSL2). Originally believed to be an antiinflammatory decoy receptor, CSL2 is now thought to playa novel and distinct role in
sepsis (160). Another CS cleavage product, the CSb, initiates the assembly of the CSb-9
membrane attack complex, which induces lysis of complement-targeted bacteria (99)
(Fig. 1).
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TLRs compnse a family of pattern recognition receptors named after their
similarity to the Drosophila Toll protein (92) (104). Their discovery in the late 1990s has
sparked a resurgent interest in innate immunity. Indeed, the study of TLRs has helped
appreciate the economical specificity of the innate immune system and that adaptive
immunity did not evolve to replace innate immunity, but rather evolved around it. TLRs
are transmembrane glycoproteins comprising an N-terminalleucine-rich repeat domain, a
transmembrane region, and a C-terminal cytoplasmic signaling domain (71) (75). These
receptors are primarily expressed by first-line professional phagocytes (e.g., neutrophils,
macrophages, and dendritic cells) and are thus strategically located for early recognition
of microbial pathogens (1).

To date, 10 human TLRs have been identified which

generally sense and respond to distinct types of microbial structures (Fig. 2).
instance, TLR3

For

responds to double-stranded viral RNA, TLR4 responds to

enterobacterial lipopolysaccharide, TLR5 to bacterial flagellin, and TLR9 to microbial
CpG DNA. TLR2 is unique in that it heterodimerizes with signaling partners (TLRI or
TLR6) for detecting and responding to microbial cell wall components, such as
lipoteichoic acid, lipoproteins, yeast zymosan or fimbriae (1) (10) (80).
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Classical

Lectin

Ag-Ab

MBl

Alternative
C3(H 2 0)
Properdin, lPS/lOS

Pathway-specific C3 convertases

!

Figure 1. Activation pathways of the complement system. All three pathways

converge at a central step, involving activation ofthe third component of
complement (C3) by pathway-specific C3 convertases. Proteolytic cleavage of a
series of proteins downstream of C3 leads to the generation of potent effector
molecules. These include the anaphylatoxins C3a and CSa, which activate specific
receptors (C3aR and CSaR). Moreover, CSa also interacts with the modestly
characterized CSa receptor-like 2 (CSL2) (81). Additional effectors generated
downstream of C3 are the opsonins C3b and iC3b, the latter of which coats
microbes and promotes their phagocytosis by complement receptor-3 (CR3). In
the terminal pathway, CSb initiates the assembly of the CSb-9 membrane attack
complex (MAC), which in turn induces microbial cell lysis (96).

6

Those TLRs which are mainly responsible for detecting extracellular microbial
structures are expressed on the host cell surface (TLRs 1, 2, 4, 5, and 6), whereas those
specializing in detecting viral or bacterial nucleic acids are appropriately located
intracellularly on endocytic vesicles or organelles (TLRs 3, 7, 8 and 9) (Fig. 2).
Following ligand binding, TLR signaling is triggered upon recruitment of adaptor
proteins to the cytoplasmic TLR domains, which help propagate the signals to
downstream kinases and transcription factors.

This ultimately leads to induction of

immunoregulatory genes that activate or suppress the innate immune and inflammatory
response (116) (117).

The presence of both common and selective adaptors, in

conjunction with the apparent compartmentalization of the TLRs, allows the induction of
individual signaling pathways (for at least some TLRs) in addition to a core TLR
response (117). It is thus possible that activation of diverse TLR intracellular pathways,
dependent upon different TLR ligand specificities, may allow the host to tailor a response
that is appropriate against a given pathogen.
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Figure 2. Microbial ligand specificites of human Toll-like receptors (TLRs).
TLR2, in cooperation with its signaling partners, TLRI or TLR6, detects mostly
microbial cell wall components, such as lipoprotein, lipotechoic acid (L TA) or
fimbrae (1) (12). TLR4 and TLR5 recognize lipopolysaccharide (LPS) and
bacterial flagellin, respectfully, whereas no ligand has been identified for
TLRIO. Endosomal TLRs such as TLR3, recognizes double-stranded viral
RNA, whereas TLR7 and TLR8 recognized single-stranded viral RNA and
TLR9 detects microbial CpG DNA.
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Both complement and TLRs are rapidly activated by most pathogens upon
encounter with the host, and common microbial molecules like gram-negative bacterial
lipopolysaccharide and yeast zymosan can act both as TLR ligands and complement
activators. It is conceivable that the coordination of the early innate response would
require a crosstalk between the complement and the TLR systems. In this regard, a
systematic analysis of crosstalk in intracellular signaling pathways has revealed that a
great number of microbe-induced stimuli converge on a relatively limited number of
effector signaling pathways (113).

In principle, a molecular crosstalk between

complement and TLRs could result in cross-regulation of the two systems, including
potential synergistic or even antagonistic interactions. These interactions may help
enhance host defense or regulate it to prevent excessive inflammatory responses.
However, it is also plausible that at least some crosstalk interactions may be instigated by
the pathogens themselves for deregulating or modifying the host response in a way that
favors their survival. Though only recently has this issue started to be addressed,
available evidence indicates bidirectional cooperation between the complement and the
TLR system, since complement regulates TLR activation (63) (165), whereas TLR
signaling transmodulates the activity of complement receptors (57) (61).

9

Periodontitis, associated bacteria, and complementffLR immunity

Periodontal disease is possibly the most common chronic disorder of infectious
origin in humans, resulting in inflammatory destruction of the tooth-supporting tissues
(123). The disease is initiated by certain species of subgingival gram-negative anaerobic
bacteria co-existing within dynamic communities of highly-organized architecture (24)
(144), originally termed "dental plaque" which predates the more modem term "biofilm"
(41) (106). In periodontal health, the ordered structure of the dental plaque biofilm
consists predominately of gram-positive, facultative anaerobic bacteria, although the
onset of the disease is associated with a shift to gram-negative anaerobic bacteria which
begin to colonize the subgingival pocket with greater frequencies (145). Using a colorcoded system, Socransky and colleagues characterized these microbial communities as
red, orange, green, purple and yellow complexes, on the basis of cluster analysis,
community ordination, and associated disease severity (146). A high prevalence of red
complex members such as Porphyromonas gingivalis, Treponema dentico/a, and

Tanerella forsythia correlates strongly with periodontal tissue destruction (65) (146).
Prevotella intermedia and Fusobacterium nucleatum, both members of the orange
complex, are also associated with various forms of periodontal disease (21) (146) (162).
While the bacteria constitute an essential etiologic factor, it is the host
inflammatory reaction to bacterial challenge that primarily mediates periodontal tissue
damage (37). This is not to say, however, that the challenge in periodontitis involves
simply the issue of controlling the inflammatory response. In a related context, purely
anti-inflammatory therapies in sepsis clinical trials have generally failed even if the initial
hyper-inflammatory stage was controlled; indeed, many patients would succumb to the
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infection itself at later stages of the disease (134). Therefore, periodontal and other
infection-driven inflammatory diseases should be dealt with in ways that address both
infection and inflammation.

This in turn requires adequate understanding of both

protective and destructive aspects of the host response and how pathogens may evade the
former and contribute to the latter.
There is strong evidence that complement and TLRs form an important link
between infection and various local or systemic autoimmune or inflammatory conditions,
such as septic shock, ulcerative colitis, rheumatoid arthritis, systemic lupus
erythematosus, atherosclerosis, ischemialreperfusion injury, and asthma (2) (17) (131)
(160).

There is also evidence for complement and TLR involvement in periodontal

disease. In this regard, a profusion of complement proteins and derived split products are
found within the gingival crevicular fluid of periodontitis patients, composing up to 70%
of that found in the serum (127). The functionality of the complement components of the
gingival crevicular fluid has been confirmed (18), whereas activated complement
fragments have also been detected in the gingival connective tissue (18). Importantly,
induction of experimental gingivitis in human volunteers causes progressive elevation of
complement cleavage products and correlates with increased microbial plaque
accumulation, clinical inflammation, and bleeding on probing (122). These clinical
findings suggest a role for complement involvement in periodontal pathogenesis.
Moreover, in vitro mechanistic studies have demonstrated complex interactions between
periodontal bacteria and the complement system (58) (103) (125).
In addition to elevated complement activity, the inflamed periodontium is
infiltrated by TLR-expressing inflammatory cells, whereas healthy gingiva display
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significantly lower levels of TLR expression (110) (111) (129). Besides professional
inflammatory cells, gingival epithelial cells and fibroblasts also express TLRs and the
level of expression correlates with disease activity (84) (129) (148) (159). In terms of
function, TLRs (particularly TLR2 and to a much lesser extent TLR4) have been shown
to regulate important immune and inflammatory responses to periodontal bacteria in vivo
and in vitro (3) (11) (16) (23) (33) (54) (59) (118) (164).
However, the precise roles, whether protective or destructive, played by the
complement and the TLRs in periodontal infection and inflammation are poorly
understood. This is partly because these issues have not previously been systematically
investigated. Nevertheless, a substantial body of available literature exists, which, if
properly synthesized and interpreted, could provide important new insights for future
studies.

Porphyromonas gingivalis: master of subversion

In principle, a host inflammatory response can become destructive when it is
deregulated and its magnitude gets out of proportion to the microbial threat, or when it is
undermined by pathogens leading to persisting but ineffective inflammation in terms of
infection control (37) (49) (83) (135). In the context of periodontitis, P. gingivalis could
be reasonably characterized as a master of subversion, on the basis of sophisticated
sabotage tactics presented below. This gram-negative anaerobic organism expresses an
elaborate system of adhesins and proteolytic enzymes (e.g., long and short fimbriae,
hemagglutinins, and Arg- and Lys-specific cysteine proteinases known as gingipains),
which coordinately enable the pathogen to colonize host tissues and secure critical
nutrients (89). As important as these virulence features may be, P. gingivalis would
12

probably be unable to establish a chronic infection, unless it could have also evolved
ways to evade, undermine, or trick the host immune system. This is lucidly exemplified
by its capacity to not only subvert both complement and TLR immunity but, moreover, to
exploit crosstalk signaling pathways between complement and TLRs.

Neutralization of complement action

P. gingivalis causes significant inhibition of complement activation, regardless of
the initiation pathway involved (classical, lectin, or alternative; Fig. 1), through
gingipain-dependent degradation of key complement components, such as the C3 (126)
(142). As a consequence, the deposition of opsonins or the membrane attack complex on
the pathogen surface is suppressed, unless its gingipain activity is ablated by chemical or
genetic means (139) (143).

All three gingipain enzymes participate in complement

inactivation, although the Arg-specific enzymes (HRgpA and RgpB) are more potent in
this regard than the Lys-specific gingipain (Kgp) (125). As a further safety measure, the
pathogen appears to hijack physiological mechanisms of inhibiting the complement
cascade. In this regard, P. gingivalis uses its HRgpA to capture the circulating C4bbinding protein on the bacterial cell surface, thereby acquiring the ability to negatively
regulate the classical pathway C3 convertase (128).
The above summarized findings are consistent with observations that P. gingivalis
is exquisitely resistant to the lytic action of complement (125) (143).

Curiously,

however, Arg- and Lys-gingipain mutants are as resistant as the wild-type organism upon
their exposure to human serum, even though active complement fragments are readily
deposited on their bacterial surface (143).

These intriguing observations suggest an

inherent protective mechanism that is independent of complement inactivation. Indeed, a
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surface amomc polysaccharide was implicated in this inherent resistance smce P.
gingiva lis mutants lacking this structure become readily susceptible to complement-

mediated lysis (143).

Although this anionic polysaccharide may directly confer

resistance, the possibility for an indirect effect may not formally be ruled out. In this
context, certain pathogens (e.g., Helicobacter pylori and Escherichia coli) acqUIre
resistance against complement lysis by expressing molecules that can bind CD59, a host
regulatory protein which inhibits the terminal step of the membrane attack complex
formation (88).
It, therefore, appears that P. gingivalis may be usmg a number of different

reinforcing mechanisms to ensure its survival in the presence of complement. In this
regard, since the inhibitory mechanisms of P. gingivalis against complement activation
are leaky (125), it makes sense that it has also developed inherent resistance against
complement-dependent lysis. However, ifthe surface anionic polysaccharide is sufficient
to provide inherent protection, a plausible question is why the pathogen has additionally
evolved ways to suppress a system that cannot kill it. An interesting interpretation is that
P. gingivalis may have evolved complement inactivation capacity not for its own

protection, but for the benefit of other organisms occupying the same subgingival niche.
This action may not be as altruistic as it seems; it may actually offer a survival advantage
for P. gingivalis, as it depends on other periodontal bacteria for enhanced colonization
and full expression of virulence (74) (78) (124). Since P. gingivalis is resistant to the
lytic action of complement (125) (143), the ability of the complement system to directly
offer host protection against this organism is seriously questioned.

Nevertheless, it

cannot be ruled out that complement activation may indirectly fight this pathogen through
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the recruitment and activation of phagocytic cells. However, P. gingivalis may have
evolved strategies to diminish or evade its destruction by phagocytes in the presence of
complement.

Evasion and subversion of TLRs

Available evidence suggests that P. gingiva lis may have also evolved ways to
evade or subvert the TLR system, which senses this organism primarily through TLR2, as
shown in vitro and in vivo (11) (54). On the other hand, TLR4 appears to play little or no
role in cell activation in response to this oral bacterium (11) (54). These observations
appear curious given that P. gingivalis is a gram-negative organism which expresses a
lipopolysaccharide. However, the organism elegantly utilizes specific lipid A 1- and 4'phosphatases and a deacylase which in concert generate a tetra-acylated and
dephosphorylated

lipid

A

structure

(14).

This

modification

renders

the

lipopolysaccharide molecule biologically inert, thereby allowing P. gingivalis to evade
TLR4 activation (14). At the same time, this modification confers protection against
polymyxin B and perhaps other cationic anti-microbial peptides (14). Intriguingly, the
presence of high concentrations of hemin (an environmental nutrient found in diseased
sites) suppresses lipid A I-phosphatase activity and leads to the production of a monophosphorylated lipid A, which actively antagonizes TLR4 activation (14) (15). Thus,
even though P. gingivalis may express other molecules with intrinsic TLR4 agonistic
activity, TLR4 activation is likely suppressed in the context of the whole organism (Fig.
3), as seen both in vitro and in vivo (11) (54). In this regard, P. gingivalis behaves like
certain other, non-oral pathogens which have also opted to modify their surface structures
so as to escape TLR4 recognition (5) (108) (141).
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The above considerations may explain why TLR2, rather than TLR4, is the
predominant TLR involved in P. gingivalis recognition. Induction of TLR2 signaling by

P. gingivalis requires a signaling partner (TLRI or TLR6), takes place in membrane lipid
rafts where the receptors are recruited ad hoc, and is facilitated by a non-signaling coreceptor (CDI4) which constitutively resides in lipid rafts (54). Although the host TLR2
response may be potentially protective, P. gingivalis has developed ways to undermine
the intended host response. Indeed, the pathogen was shown to manipulate the TLR2
response by instigating a molecular crosstalk between TLR2 and the CXC-chemokine
receptor 4 in macrophage lipid rafts (59).

Specifically, the binding of P. gingivalis

fimbriae to CXC-chemokine receptor 4 induces cAMP-dependent protein kinase A
signaling, which in turn suppresses TLR2-dependent activation of nuclear factor-KB and
induction of nitric oxide (Fig. 3) (59).

The inhibition of production of this key

antimicrobial molecule promotes the ability of P. gingiva lis to survive in vitro and in vivo
(59).
The impact of TLR2 signaling on the ability of P. gingivalis to cause
experimental periodontitis was examined by two independent studies, which found that
TLR2-deficient mice (but not TLR4-deficient or wild-type controls) are protected against
periodontal bone loss (11) (42). These findings are consistent with the notion that TLR2
signaling is manipulated by P. gingivalis in a way that promotes its virulence. However,
an alternative or additional interpretation is that the observed enhanced bone loss in
normal mice could be attributed to P. gingivalis induction of TLR2-mediated
inflammatory osteoclastogenesis (154).
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Figure 3. Evasion or subversion of Toll-like receptor (TLR)
activation by Porphyromonas gingivalis. P. gingivalis can either evade
or actively antagonize TLR4 activation via a modified lipid A structure
of its lipopolysaccharide (14) (62). Although activation of TLR2 is not
antagonized at the receptor level, P. gingivalis instigates a molecular
crosstalk between the CXC-chemokine receptor 4 and TLR2. Unlike
CD14, which facilitates TLR2 activation by the pathogen (56), CXCR4
suppresses TLR2 signaling via cyclic AMP-dependent protein kinase A
(PKA) signaling, which in turn inhibits the activation of nuclear factorkappaB (NF-KB) activation (59) (161).
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Exploitation of crosstalk interactions between TLRs and complement

TLR2 activation by P. gingivalis induces two distinct signaling cascades (57).
One of the cascades leads to induction of pro-inflammatory and antimicrobial responses,
and represents the pathway that is manipulated by P. gingivalis through exploitation of
CXC-chemokine receptor 4. The other cascade represents a pro-adhesive pathway and
involves a crosstalk between TLR2 and the complement system (57). Specifically, P.
gingivalis induces TLR2 inside-out signaling which transactivates the adhesive capacity

of complement receptor-3 (62) (Fig. 4). This crosstalk is made possible by the property
of complement receptor-3 to cluster with TLRs in lipid rafts of P. gingivalis-stimulated
cells (54). Once transactivated, however, complement receptor-3 becomes a target of
subversive activity by P. gingivalis.
Indeed, P. gingiva lis uses its fimbriae to bind complement receptor-3, which in
turn mediates the uptake of this oral pathogen by macrophages (56). Intriguingly, this
phagocytic mechanism does not promote the killing of P. gingivalis (158), possibly
because complement receptor-3 is not linked to vigorous microbicidal mechanisms (135).
In contrast, when P. gingivalis is phagocytosed by alternative receptors, i. e., when
complement receptor-3 is blocked or genetically ablated, the intracellular killing of this
pathogen is dramatically enhanced (158).
The interaction of P. gingivalis with complement receptor-3 also activates the
extracellular signal-regulated kinase 112, which in tum selectively inhibits mRNA
expression of the p35 and p40 subunits ofinterleukin-12 (53) (Fig. 4).
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Figure 4. Crosstalk pathways between Toll-like receptors and complement
in P. gingivalis activated macrophages. TLR2 recognition of P. gingivalis,
induces PI3K-dependent inside-out signaling which trans activates CR3, thereby
inducing ERKI 12 signaling that downregulates the expression of messenger
RNA for cytokines of the IL-12 family (53) (54). Moreover, P. gingivalis uses
its gingipains to attack C5, consequentely releasing biologically active C5a that
can activate PI3K and ERKI 12 through its receptor (C5aR), in turn suppressing
critical transcription factors required for expression of cytokines of the IL-12
family (15) (63) (124). Intriguingly, IL-12 inhibition though these mechanisms
results in impaired immune clearance of P. gingiva/is in vivo (53), suggesting
that the pathogen exploits TLR- complement crosstalk signaling to promote its
virulence.
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Interleukin-12 (IL-12) is a key cytokine involved in pathogen clearance through
regulatory effects on the production of interferon-y, which is a potent activator of the
macrophage microbicidal capacity (IS3).

Consistent with the above, wild-type mice

elicit lower levels of interleukin-12 and interferon-y and display impaired clearance of P.
gingivalis systemic infection compared to mice that lack complement receptor-3 (S3).

Similar results are seen after CR3 blockade with a specific antagonist that suppresses P.
gingivalis induction of periodontal bone loss in mice (S3). In brief, there is compelling

evidence that complement receptor-3 constitutes an Achilles' heel which confers host
susceptibility to P. gingivalis infection. In this regard, it seems likely that P. gingivalis
may have actually co-opted a natural anti-inflammatory mechanism to evade innate
immunity. Specifically, complement receptor-3 is heavily committed to phagocytosis of
iC3b-coated apoptotic cells, which are not normally recognized as danger (76) (10S).
This precludes induction of a vigorous host response and, in fact, production of
interleukin-12 is inhibited following phagocytosis of apoptotic cells by macrophages
(76).
Although P. gingivalis inhibits the complement cascade, curiously enough, the
pathogen proactively generates one of the active complement fragments. Specifically, all
three gingipains (HRgpA, RgpB, and Kgp) act in a CS convertase-like manner and
generate biologically active CSa through limited degradation of CS, whereas the CSb
remnant is functionally inert (12S) (161). When CS is oxidized by hydroxyl radicals (as
may occur in the oxidative environment of the inflammatory response) the gingipains
generate increased CSa biological activity (31).

Furthermore, P. gingiva/is may

indirectly generate functional CSa by exploiting the physiological crosstalk between the
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coagulation and the complement systems, which activates the so-called extrinsic pathway
(66) (Fig. 1). Indeed, HRgpA and RgpB activate pro-thrombin to form thrombin (68)
which, in turn, generates biologically active C5a by acting as a C5 convertase (66) (Fig.
1). Although C5a can potentially playa key role in host defense against infection (46), it
seems highly unlikely that P. gingivalis uses its enzymes to generate C5a to contribute to
its elimination.
An intriguing question, therefore, is whether there is any selective pressure or
advantage for P. gingivalis to specifically generate C5a, given that this chronically
persisting pathogen overall inhibits the complement cascade. A possible scenario is that
local generation of excessive levels of C5a could incapacitate the antimicrobial function
of gingival crevicular neutrophils rendering them less threatening to P. gingivalis. This is
because neutrophils become immunologically paralyzed in the presence of high
concentrations (10-100 nM) of C5a and thereby fail to carry out functions such as
chemotaxis, phagocytosis, and production of antimicrobial and inflammatory mediators
(67) (160). Such immunological dysfunction has been seen both in vitro and in vivo and
involves both human and rodent neutrophils (67) (132) (160). In fact, C5a-mediated
inhibition of neutrophil killing of P. gingivalis does occur, both in vitro and in vivo (1.
Krauss and G. Hajishengallis, unpublished data). However, the underlying mechanisms,
whether involving immune paralysis or alteration of specific signaling pathways, are
currently under investigation. In addition to its potential exploitation by P. gingivalis,
C5a may amplify periodontal tissue damage through its ability to recruit and activate
inflammatory cells. For example, enhanced production of reactive oxygen species by
C5a-stimulated neutrophils (46) may contribute to oxidative periodontal tissue
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destruction (12). On the other hand, this host response would not affect P. gingivalis,
since it is resistant to killing by reactive oxygen species (55) (111).
Even if the gingipain activity of P. gingiva lis is capable of increasing the
microenviromental C5a concentrations to paralyzing levels for the neutrophils, this would
not impinge on the function of macrophages, which can also be recruited to the gingival
crevice or additionally interact with the pathogen in the periodontal connective tissue (28)
(150). Indeed, macro phages are quite resistant to the deleterious effects of high C5a
concentrations, because they express relatively modest levels of the C5a receptor relative
to neutrophils (160). For instance, whereas the ability of neutrophils to induce tumor
necrosis factor-a (and other innate responses) is inhibited in the presence of C5a at 2: 10
nM, the macrophages display potentiated tumor necrosis factor-a responses under the

same C5a concentrations (67) (132).
Therefore, even at high levels, C5a does not exert a general immunosuppressive
influence on macrophages.

Strikingly, however, C5a can specifically downregulate

cytokines of the interleukin-12 family. Indeed, C5a-induced signaling in macrophages
interferes with TLR-induced expression ofmRNA for the interleukin-12 p35, interleukin12/interleukin-23 p40, and interleukin-23 p19 subunits (63) (85).

These regulatory

effects are possibly mediated through C5a-induced phosphatidylinositol-3 kinase and
extracellular signal-regulated kinase 112 signaling, which in concert suppress critical
transcription factors, the interferon regulatory factor-l and -8 (63) (Fig. 4). At the protein
level, the production of interleukin-12 is inhibited both in vitro and in vivo, leading to
suppression ofT-helper type 1 cell-mediated immunity (63) (165). Moreover, the ability
of C5a to inhibit mRNA expression of both interleukin-23 subunits strongly suggests that
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CSa can interfere with the capacity of this cytokine to support the development of the Thelper type 17 cell subset (9). The physiological significance of these CSa regulatory
effects is likely to attenuate potential tissue damage mediated by T-helper type 1 and Thelper type 17 cells, as seen in various pathological inflammatory conditions (37) (9S)
(138).

However, undesirable outcomes may arise when CSa is not produced

physiologically but through the uncontrolled action of microbial enzymes, such as the P.
gingivalis gingipains.

Since interleukin-12 is important for immune control of P.

gingivalis (S3), it is possible that this pathogen may exploit the CSa-induced crosstalk

with TLR2 for inhibiting IL-12-dependent immune clearance. Such evasion mechanism
may be complementary, rather than redundant, since the interaction of P. gingivalis with
complement receptor-3 causes partial inhibition ofinterleukin-12 production (about 60%)
(S3).

The notion that P. gingivalis hijacks CSa for its own benefit is additionally

supported by observations that the intracellular survival of this pathogen in macrophages
is promoted in the presence of CSa (1S7).
Interestingly, unlike CSa, C3a is extensively degraded by P. gingivalis gingipains
and does not retain biological activity (161). Whether this is beneficial for the pathogen
is uncertain, but it should be noted that C3a exerts direct antimicrobial effects and readily
kills both gram-negative and gram-positive bacteria such as E. coli, Pseudomonas
aeruginosa, and Enterococcus faecalis (114). If C3a can kill P. gingivalis as well, then

its gingipain-mediated inactivation would serve to protect P. gingivalis.
In summary, it appears that P. gingiva lis does not have a purely defensive agenda
in dealing with the complement system. In other words, the pathogen may not restrict its
action to simply inhibiting the complement cascade, but rather may proactively employ
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specific complement components (such as the complement receptor-3 and the C5a) for
bidirectional crosstalk interactions with TLR2 that favor the pathogen (Fig. 4).
Therefore, we hypothesized that P. gingivalis can modulate TLR2 signaling by co-opting
C5a receptor to instigate a subversive crosstalk that promotes its adaptive fitness. We
speculated this may involve blunting the killing efforts of recruited leukocytes, without
causing a wholesale immunosuppression.

Moreover, this pathogen-induced crosstalk

may serve to amplify select aspects of the inflammatory response, thereby liberating
essential peptide nutrients essential for growth without promoting the antimicrobial
defenses of recruited leukocytes that would likely facilitate its destruction.
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CHAPTER TWO: MATERIALS AND METHODS

Materials and reagents

Carboxy methyl cellulose (CMC) was purchase from MP Biomedicals, Solon,
OH.SQ22536, H89, SB216367, 8-Br-cAMP, AMD3100, forskolin, L-NAME (N(G)nitro-L-arginine methyl ester), D-NAME (N(G)-nitro-D-arginine methyl ester), and
EGTA were purchased from Sigma-Aldrich.
thapsigargin were obtained from Calbiochem.

Chelelythrin, PKI 6-22, KT5823, and
PD98059 was from Cell Signaling

Technology. Mouse-specific monoclonal antibodies to TLR2 [clone 6C2] was from eBioscience, TLR5 [85B152.5] from Abcam, and C5aR (20170) from Cedarlane
Laboratories or Hycult. Mouse rIFN-y was from the R&D Systems. Mouse rC5a was
purchased from R&D Systems and rC3a from Cell Sciences. The cyclic hexapeptide
AcF(OP(D)ChaWR) (acetylated phenylalanine-(ornithine-proline-(D) cyclohexylalaninetryptophan-arginine), also known as PMX-53, is a specific and potent C5a receptor
(CD88) antagonist, was synthesized in the laboratory of John D. Lambris, as previously
described (35) (98). A8~71-73, also a generous gift of John D. Lambris, a dual antagonist
of both C5aR and C5a-like receptor-2, was generated essentially as previously described
(49). Specifically, the A8~71-73 sequence (49) was created by three cycles of mutagenesis
of the original human C5a construct (47), using the QuickChange XL Site-Directed
Mutagenesis Kit from Stratagene. The three pairs of complementary primers used for
mutagenesis are as follows (forward sequences given):
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I) 5' -GTTACGATGGAGCCGCCGTTAATAATGATG-3',
2) 5' - CCGTGCTAATATCTCTTTTAAACGCATGCAATTGGGAAGG-3',
3) 5' -CTCTTTTAAACGCTCGTGAAAGCTTAA TTAGC-3',
corresponding to mutations I) C27A, 2) H67F and D69R, and 3) M70S and i\(71-74),
respectively. The protein was then expressed and purified as previously described (47).
All reagents were used at optimal concentrations determined in preliminary or published
studies by our laboratories (36) (47) (59) (113) (165).

C5a and C3a were used at

concentrations up to 50 nM and 100 nM, respectively, which are widely used for in vitro
experiments (63) (165). Moreover, these concentrations are consistent with observations
that under inflammatory conditions, C5a and C3a may reach serum levels as high as 100
nM and 400 nM, respectively, although even higher levels may be generated at local sites

of inflammation (149) (160).

All reagents were used at optimal concentrations

determined in preliminary or published studies by our laboratories (59) (94) (98). When
appropriate, dimethyl sulfoxide (DMSO) was included in medium controls and its final
concentration was

~

0.2 %.

Animals

Both female BALB/c and C57BLl6 C5aR-deficient mice (with their respective
wild-type controls) were used in these studies. The TLR2-deficient mice were originally
C57BLl6 (The Jackson Laboratory) and we backcrossed them for nine generations onto a
BALB/c genetic background prior to use in these studies. The C5aR-deficient mice were
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originally obtained from Dr. Craig Gerard (Harvard Medical School) and are now housed
at The Jackson Laboratory. All animal procedures were approved by the Institutional
Animal Care and Use Committee and performed in compliance with established federal
and state policies.

Culturing of bacterial strains
P. gingivalis ATCC 33277 and its isogenic KDP128 mutant, which is deficient in

all three gingipain genes (rgpA, rgpB, and kgp) (45) (kindly provided by Dr. K.
Nakayama, Nagasaki University, Japan), were grown anaerobically from frozen stocks on
modified Gifu anaerobic medium-based blood agar plates for 5-6 days at 37°C, followed
by anaerobic subculturing for 18-24 hours at 37°C in modified Gifu anaerobic medium
broth (Nissui Pharmaceutical).

Oral gavage model
Oral infection of mice proceeded as previously described by Baker et al (8). In
brief, Balb/c mice were provided antibiotic-supplemented drinking water (800 mg
sulfamethoxazole and 400 mg trimethoprim per liter of water) for 10 days prior to
experiment.

Following a 3 day regimen of antibiotic-free water, mice were orally

infected with a 109 suspension in 2% CMC in PBS of P. gingivalis, repeated every other
day for a total of 5 inoculations.

Six weeks following the final inoculation, total

anaerobic counts of bacteria were enumerated from paper-point samples grown under
anaerobic conditions on blood agar plates for 7 days. Moreover, periodontal bone loss
was determined by subtracting the measured distance from the cemento-enamel junction
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(CEJ) to the alveolar bone crest (ABC) of P. gingivalis-infected from the group of shaminfected mice. Results are expressed as mm change in bone loss.

Subcutaneous chamber model

lsofluorane anesthetized Balb/c mice were dually implanted with a surgical-grade
titanium coil chamber. Following a 7 day healing period, P. gingivalis (109 CFU in 100
III of PBS) was injected into the chambers of each mouse.

Chamber exudates were

harvested from mice at indicated time points and centrifuged at 1000 rpm for 5 minutes.
Subsequently, recruited cells were phenotypically characterized by flow cytometry and
supernatants were used to determine viable counts of P. gingivalis.

Intracellular survival assay in murine macrophages

Thioglycollate-elicited macrophages were isolated from the peritoneal cavity of
wild-type or mice deficient in TLR2, TLR4, C3aR, or C5aR (The Jackson Laboratory)
(54) (165), in compliance with established federal guidelines and institutional policies.
The macrophages were cultured at 37°C and 5% CO2 in RPMl 1640 (Invitrogen)
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 units/ml penicillin
G, 100 Ilg/ml streptomycin, and 0.05 mM 2-ME. None of the experimental treatments,
including treatments with C5a up to 100 nM, affected cell viability (monitored by the
CellTiter-Blue™ assay; Promega) compared to medium-only treatments. The viability of
phagocytosed P. gingivalis was monitored by an antibiotic protection-based intracellular
survival assay, as previously described (158). Briefly, mouse peritoneal macrophages
were allowed to phagocytose P. gingivalis (MOl = 10: 1; 5 x 106 bacteria and 5 x 105
cells) for 30 min at 37°C. This was followed by washing to remove extracellular non-
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adherent bacteria and I-hour treatment with antibiotics (300 Ilg/ml gentamicin and 200
Ilg/ml metronidazole) to eliminate residual or extracellular adherent bacteria.

The

macrophages were subsequently cultured overnight (for a total of 24 hours) or for 48
hours. Immediately after, the macrophages were washed and lysed in sterile distilled
water and viable counts of internalized P. gingivalis were determined by plating serial
dilutions of macrophage lysates on blood agar plates subjected to anaerobic culture (158).

Cell signaling and activation assays

Induction of nitric oxide production was assessed by measuring the amount of
N02- (stable metabolite of nitric oxide) in stimulated culture supernatants using a Griess

reaction-based assay kit (R&D Systems), as previously performed (59). Levels of cAMP
in activated cell extracts were measured using a cAMP enzyme immunoassay kit
(Cayman Chemical) (94). PKA activity in lysates of activated cells was determined using
the ProFluor™ PKA assay, according to the instructions of the manufacturer (Promega)
(59).

Phosphorylation of GSK3p on Ser9 and total GSK3p were monitored using

FACETM GSK3p ELISA kits (Active Motif).

Intraperitoneal infection (i.p.)

Upon i.p. infection of mice with P. gingivalis (5 x 107 CFU), peritoneal lavage
was performed 24 hours post-infection and the peritoneal fluid was used to enumerate
recovered CFU (following anaerobic growth on blood agar plates) and measure
production of N02- (59).
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Quantitative real-time PCR

Gene expression in resting or activated mouse macrophages was quantified using
quantitative real-time PCR. Briefly, RNA was extracted from cell lysates using the
PerfectPure RNA cell kit (5 Prime, Fisher) and quantified by spectrometry at 260 and
280 nm. The RNA was reverse-transcribed using the High-Capacity cDNA Archive kit
(Applied Biosystems) and quantitative real-time PCR with cDNA was performed using
the ABI 7500 Fast System, according to the manufacturer's protocol (Applied
Biosystems). TaqMan probes, sense primers, and antisense primers for expression of a
house-keeping gene (GAPDH) or iNOS) were purchased from Applied Biosystems.

Confocal microscopy

To examine co-localization of P. gingivalis with C5aR and TLR2, mouse
macrophages were grown on chamber slides and exposed to FITC-Iabeled P. gingivalis
for 10 min. The cells were then fixed, permeabilized, stained with Texas Red-labeled
anti-C5aR plus allophycocyanin-Iabeled anti-TLR2, and mounted with coverslips for
imaging on an Olympus FV500 confocal microscope (158).

Fluorescence resonance energy transfer (FRET)

Upon stimulation for 10 min at 37°C with P. gingivalis, mouse macrophages were
labeled with a mixture of Cy3-conjugated (donor) and Cy5-conjugated (acceptor)
antibodies. In other experiments shown in Fig. 13A, FITC-Iabeled P. gingivalis was used
as donor and TRITC-Iabeled receptors served as acceptors. The cells were washed and
fixed, and energy transfer between various donor-acceptor pairs was calculated from the
increase in donor fluorescence after acceptor photobleaching (54) (152). The maximum
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(max) and minimum (min) energy transfer efficiencies in the experimental system were
determined in control experiments as the energy transfer between two different epitopes
on the same molecule or between molecules that do not engage in heterotypic
associations, and their values are denoted by dashed lines in Fig. 13A. The conjugation
of antibodies to Cy3 or Cy5 was performed using kits from Amersham Biosciences

Statistical analysis

Data were evaluated by analysis of variance and the Dunnett multiple-comparison
test using the InStat program (GraphPad Software, San Diego, CA). Where appropriate
(comparison of two groups only), two-tailed ttests were performed. P < 0.05 was taken
as the level of significance.

All experiments were performed at least twice for

verification.
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CHAPTER THREE: MOUSE MODELS OF PERIODONTAL HOST-PATHOGEN
INTERACTIONS AND INFLAMMATION

Introduction

Periodontitis is a prevalent chronic inflammatory disease that affects the toothsupporting tissues and can exert a systemic impact on health (73) (123) (151). A group
of tooth-associated subgingival anaerobic bacteria is strongly associated with
periodontitis (146), however, it is the host inflammatory response to uncontrolled
bacterial challenge that primarily mediates periodontal tissue destruction (37) (43) (72).
Although no single animal model can faithfully reproduce all aspects of periodontitis (or
any other disease), the power and significance of animal models involves their capacity to
test specific hypotheses involving distinct aspects of periodontal pathogenesis (44).
Knowledge gathered ... from different but·· complementary models can be synthesized
appropriately to obtain unique insights into the mechanisms of periodontitis. Despite
their limitations, animal models are absolutely necessary for determining cause-andeffect relationships and for assessing the potential of novel therapeutic compounds. Such
studies cannot be adequately served by in vitro experiments.

Moreover, causal

mechanistic relationships cannot normally be addressed in human studies which are often
correlative in nature (44). It should also be noted that clinical trials can be initiated only
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after safety and efficacy has been demonstrated in animal models. As models of human
disease, mice provide unique advantages beyond their relatively low cost and ease of
handling. These include extensive background information on their immune system and
a wide range of immunologic and cellular/molecular reagents. Moreover, the availability
of a host of transgenic mouse lines can be used to study the impact of specific
immunoregulatory genes.

Inflammatory periodontal bone loss: the oral gavage model

A mouse periodontitis model was developed by Baker and colleagues (6) (7) (8)
('Baker' or 'Oral gavage' model) and is now widely used with various modifications.
Reproducible gingival inflammation and alveolar bone loss can be induced in this model
following oral gavage with Porphyromonas gingivalis (7) (158) or other periodontal
pathogens, such as Aggregatibacter actinomycetemcomitans (38) (115), Tannerella
forsythia (140) or Porphyromonas gulae, an animal periopathogen equivalent to human

p. gingivalis (60). The model can be further modified to involve a co-infection, e.g., P.
gingivalis and Fusobacterium nucleatum (78) (124). Additionally, the oral gavage model

of periodontitis has been used for rapid and cost-effective identification of pathogenic
mechanisms and potential therapeutics (7) (38) (42) (53) (86) (115). Specifically, these
mouse studies have helped determine the role of defined innate receptors or cytokines in
periodontal tissue destruction, substantiate a genetic basis for host susceptibility or
resistance to periodontal disease, identify virulence factors and evasion strategies of
periodontal pathogens, and offer potential mechanistic links between periodontal and
systemic diseases (44).
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Figure 5. Oral gavage model of P. gingivalis-induced mouse
periodontitis. (A) Timeline of the experimental protocol. (B) Oral
inoculation of mice with P. gingival is using a ball-ended feeding
needle. The mouse is restrained by grasping the skin over the
shoulders and holding the tail.
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Host cell-periodontal bacteria interactions: the subcutaneous chamber model

A widely used mouse model to study host-pathogen interactions is the so-called
chamber model, which was introduced to periodontal research by Genco and colleagues
(39). The chamber comprises a coil-shaped titanium wire that is surgically implanted
subcutaneously into the mid-dorsal region of the mouse. As the exterior encapsulates
with connective tissue during the healing phase of implantation, the interior lumen
becomes increasingly hypoxic (44), creating an environment reminiscent of the
periodontal pocket.

Oral bacteria can be injected into the chamber lumen and their

interactions with recruited inflammatory cells can be assessed accurately and
quantitatively (11) (39) (111). A major advantage of the chamber model is that some of
these parameters, especially monitoring viable species-specific bacterial counts, are
difficult to assess quantitatively in mucosal infection models. Additionally, inflammatory
responses of recruited leukocytes can also be evaluated. Moreover, long-term versions of
the chamber model can be used to monitor respective leukocyte populations recruited into
the chamber or to study bacterial interactions over time. This model is thus appropriate
for investigating interactions of periodontal bacteria with recruited inflammatory cells
under conditions that faithfully mimic the subgingival environment.
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Figure 6. Subcutaneous chamber model. (A) Subcutaneous implantation of
surgical grade titanium-coil chamber. (B) Intrachamber injection of P. gingivalis
(10 9) following 7 day healing period. Aspiration (C) of chamber fluid,
immediately following desired inoculation period, and collection (D) for further
analysis.
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Results

P. gingivalis augments the population of indigenous microflora in the oral gavage

model

To ascertain the effects of oral challenge with P. gingivalis (Pg) on the recovery
of indigenous anaerobic bacteria residing within the oral cavity, total colony formingunits (CFUs) were enumerated and contrasted to CFUs recovered from sham-infected
mice (Fig. 7B). Our results clearly demonstrate that the presence of P. gingivalis (Pg)
significantly augments the population size of resident oral anaerobic bacteria recovered
by paper-point sampling from the oral cavity compared to sham-infected control mice.
Indeed, the co-presence of P. gingivalis (Pg) within the periodontium potentiated the
overall number of indigenous oral microflora by two orders of magnitude.

Neutrophils are impaired in their ability to promote the clearance of P. gingivalis in
the subcutaneous chamber model

Using the subcutaneous chamber model, we monitored inflammatory cell
recruitment and investigated the fate of P. gingivalis within an in vivo setting that closely
mimics the environment of the periodontal crevice. We observed that the overwhelming
majority of cells recruited in response to intrachamber challenge with P. gingivalis were
neutrophils (>97% at 24h post-infection) (Fig. SB). However, we found that despite a
massive influx into the chamber, neutrophils were impaired in their ability to adequately
clear the infection, observed at either early or late time points (Fig. SA).
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Figure 7. Recovery of total anaerobic bacteria from oral gavage model.

(A) Pre-determined buccal sites in the right maxilla (R1-R7) for measuring
CEl-ABC distances. (B) Oral infection with P. gingivalis (Pg) causes major

increases in the numbers of the indigenous oral anaerobic bacteria (p < 0.01 vs.
sham-infected mice) recovered by paper-point sampling.
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Figure 8. Analysis of chamber exudates from P. gingiva/is-chaUenged
subcutaneous chamber model. (A) Recovery of viable P. gingivalis
colony-forming units (CFUs) at 2 and 24 hours post-intrachamber
challenge. (B) Phenotypic characterization [CD3 (green), F4/80 (yellow)
and Ly6G (red)] of recruited leukocytes 24 hours post-intrachamber
infection with P. gingivalis.
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DISCUSSION

The bimodal nature of periodontal disease requires an experimental system that
can equally address both host and bacterial factors (mutually inclusive contributors) that
promote periodontal tissue destruction. Due to its experimental versatility, the mouse
oral gavage model, an in vivo experimental system (7), is a time-honored and faithful
rendition of periodontal disease. For example, through the use of genetically altered
mice, the oral gavage model can be employed to monitor changes in gene expression
within the gingival tissues as well as quantify appreciable bone loss in the presence of
keynote periodontal pathogens, such as Porphyromonas gingivalis (7) (8) (44) (58). In
addition to examining host determinants that contribute to periodontal disease, microbial
counts can also be enumerated. Intriguingly, through the use of this in vivo model, we
demonstrate that the presence of P. gingivalis can stimulate a substantial rise in the
overall numbers of indigenous oral anaerobic bacteria residing within the oral cavity (Fig.
7B). These findings suggest that alterations in the oral microbial profile correspond with
the prevalence of P. gingivalis, underscoring its importance for potentially promoting
survival and virulence of the entire microbial community (21) (22) (49) (82).
The dichotomy of both protective and destructive immunity in the periodontium
highlights the critical importance of discerning the precise roles leukocytes play with
regards to periodontal disease. Although well-accepted and heavily utilized, the oral
gavage model offers a rather panoramic readout of mucosal responses to infection.
However, the subcutaneous chamber model provides an alternative in vivo model that can
be utilized to determine specific host and bacterial factors driving both protective and
destructive aspects of periodontal disease. Our studies reveal that in response to
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challenge with P. gingivalis, the lumen of the subcutaneous chamber becomes
predominated almost exclusively by neutrophils (Fig. 8B), similar to an environment
encountered within the gingival crevice, where 2:95% of total leukocytes are indeed
neutrophils (28). Strikingly, P. gingivalis can survive and persist within the chamber
although high numbers of neutrophils are chemoattracted there (Fig. 8A). These finding
suggest that neutrophils may not be particularly adept at clearing P. gingivalis from the
gingival crevice and may, in fact, playa destructive rather than protective role in
periodontitis.
In general, the strength of the chamber model involves the whole-animal aspect
for accurately quantifiable host responses or microbiological parameters (inflammatory
cell recruitment, cytokine responses, bacterial clearance or persistence, and so on) (11)
(39) (44). Since the significance of animal models involves their capacity to test defined
concepts or hypotheses, rather than their fidelity to all aspects of a given disease (44), the
chamber model is suitable to determine how specific host response genes or putative
virulence factors shape the outcome of host interactions with periodontal bacteria (28)
(111). Therefore, the chamber model can complement the oral gavage model for a more
complete and nuanced understanding ofthe periodontal host-pathogen interplay.
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CHAPTER FOUR: MICROBIAL HIJACKING OF COMPLEMENT -TOLLLIKE RECEPTOR CROSSTALK

Introduction

Although traditionally perceived as an antimicrobial enzyme system in serum,
complement is now recognized as a central component of host defense impacting both
innate and adaptive immunity (99).

More recently, complement was suggested to

crosstalk with another major innate defense system, the Toll-like receptors (TLRs), to
apparently coordinate the host response to infection (52) (63). Not surprisingly, given its
importance in fighting pathogens, complement constitutes a key target of immune
evasion by microbes which cause persisting infections (52). Here we describe a novel
strategy of immune subversion, involving microbial exploitation of the fifth complement
component (C5) for corrupting TLR immunity via a hitherto unknown mechanism of
complement-TLR crosstalk.
The pathogen involved in these subversive interactions, Porphyromonas
gingivalis, is a gram-negative anaerobic bacterium. This organism is strongly associated

with periodontitis, a highly prevalent oral chronic inflammatory disease, and is moreover
implicated in systemic conditions such as atherosclerosis and aspiration pneumonia (10).
Although P. gingivalis inhibits the overall complement cascade regardless of the
initiation pathway involved, curiously enough, this pathogen selectively generates
biologically active C5a (69) (116). C5a generation by P. gingivalis is mediated by its
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Arg-specific cysteine proteinases (HRgpA and RgpB gingipains) which act in a C5
convertase-like manner (69) (116). Interestingly, upon release ofC5a from C5, the C5b
remnant is proteolytically destroyed by P. gingivalis (6) to apparently prevent activation
of the terminal complement pathway, which leads to the formation of the membrane
attack complex (99). Since C5a is a powerful chemoattractant and activator of
phagocytes (88), it seems counterproductive for a pathogen to actively contribute to C5a
generation. An intriguing question, therefore, is whether there is any survival advantage
for P. gingivalis to specifically generate C5a in its periodontal niche, where complement
proteins are abundantly present at up to 70% of their concentration in serum (116).
Below we present evidence that P. gingivalis paradoxically employs the proinflammatory C5a for targeted immune suppression of macrophages through a novel
crosstalk mechanism between the C5a receptor (C5aR) and TLR2, the predominant TLR
utilized by this organism in vitro and in vivo (123) (137). This is the first report for a
pathogen capable of proactively instigating and exploiting crosstalk signaling between
complement and TLRs, rather than undermining either system independently as
previously shown for a number of other microbes (52) (161).

Results

C5a and subversion of macrophage function

We were prompted to investigate whether C5a signaling is advantageous to P.
gingivalis by earlier observations that its enzymatic activity selectively generates

functional C5a, despite overall inhibiting the complement cascade (69) (116). We first
examined whether C5a influences the macrophage intracellular killing of P. gingivalis.
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Strikingly, the ability of this pathogen to survive intracellularly in mouse macrophages
was significantly promoted by C5a, but not by the related anaphylatoxin C3a (Fig.9, A
and B). This unexpected pro-microbial effect of C5a was also observed in interferon
(IFN)-y-primed macrophages (Fig. 9, C and D). The elevated viable cell counts of P.
gingivalis in C5a-treated macrophages could not be attributed to possible differences in

the initial bacterial loads, since P. gingivalis phagocytosis was not significantly affected
by the absence or presence ofC5a or C3a (data not shown).
We next investigated the mechanism(s) underlying C5a-mediated inhibition of the
macrophage intracellular killing capacity.
combined

action

of C5a

and

P.

In this regard, we hypothesized that the

gingivalis

on

macrophages

may

induce

immunosuppressive signaling. We first used real-time quantitative PCR to determine
whether C5a upregulates the expression of negative regulators of TLR signaling in P.
gingivalis-stimulated macrophages.

Although the bacterium alone upregulated the

expression of some of the investigated regulators, including the suppressor of cytokine
signaling-I, the interleukin-I receptor-associated kinase M, and the ubiquitin-editing
enzyme A20, no synergistic or additive effects were seen in the concomitant presence of
P. gingiva/is and C5a (data not shown). Therefore, these regulatory molecules are not
likely involved in C5a-mediated suppression of macrophage killing of P. gingivalis.
Moreover, although induction of cAMP can induce immunosuppressive signaling (12),
C5a by itself failed to induce a cAMP response in macrophages (Fig. 9E). Strikingly,
however, C5a synergized with P. gingiva lis resulting in >3-fold elevation of the
intracellular cAMP levels relative to P. gingivalis stimulation alone (Fig. 9E).

44

The

synergy was observed as early as 10 min after cell stimulation, peaked at 1 hour, but
significantly elevated cAMP levels were sustained for at least 24 hours (Fig. 9E).
This upregulatory effect of C5a was dose-dependent (data not shown) and was
totally

abrogated

by

a

C5aR

antagonist

(C5aRA),

the

cyclic

hexapeptide

AcF(OP(D)ChaWR) (Fig. 9F), indicating that C5a acted through the classic C5aR
(CD88), rather than the alternative C5a-like receptor 2 (C5L2).
Given that P. gingivalis is exquisitely resistant to killing by the oxidative burst
(160), we investigated whether C5a interferes with induction of nitric oxide as a possible
mechanism for its pro-microbial effect. The underlying rationale was that P. gingivalis is
sensitive to nitric oxide-mediated killing (11) (54). Indeed, C5a significantly inhibited,
via a C5aR-dependent mechanism, the production of nitric oxide in P. gingivalisstimulated macrophages, even in cells primed with IFN-y (Fig. 9G).

The C5aR

specificity of the C5a-driven augmentation of cAMP and suppression of nitric oxide in P.
gingivalis-challenged macrophages was confirmed by lack of these effects in C5aR-

deficient (C5ar- I-) macrophages (Fig. 9, H and I, respectively). In toto, our findings
suggest that C5aR activation by C5a results in suppression of P. gingivalis intracellular
killing associated with elevation of cAMP and reduction of nitric oxide.
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Figure 9. Immunosubversive effects of C5a on P. gingiva/is-challenged
macrophages. Untreated (A, B) or IFN-y primed (C, D) macrophages were
incubated with P. gingivalis in the presence or absence of C3a (200 nM) or C5a
(50 nM). Colony counts of internalized bacteria were enumerated at 24 (A, C) or
48 hours (B, D) post-infection (E) P. gingivalis-challenged macrophages, in the
absence or presence of C5a, were assayed for intracellular ~AMP production for
the times indicated. (F) Similar experiment as in (E), involving 1 hour of
incubation and the use of a specific C5a receptor antagonist (C5aRA; 1 /lM). (G)
Unprimed or IFN-y-primed macrophages were assayed for N02- production after
incubation with or without P. gingivalis, C5a, or C5aRA. Induction of cAMP (H)
and N0 2- (I) production with macrophages from wild-type or C5aR-deficient
(e5ar -1- ) mice. Data are means ± SD (n = 3) from typical experiments performed

three (A-D, F and G) or two (E, H, and I) times yielding consistent results. *p <
0.05 and **p <0.01 compared to medium only treatments . •p < 0.01 in C5a + Pg
compared to Pg alone. Inverted triangles indicate significant (P<O.Ol) reversal of
C5a effects by C5aRA or C5aR deficiency.
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C5a immunosubversive effects are strictly dependent on cAMP-PKA signaling

We investigated whether the C5a-mediated inhibition of nitric oxide production
depends upon the ability of C5a to stimulate synergistic elevation of cAMP. Indeed, the
inhibitory C5a effect on nitric oxide was reversed in macrophages pretreated with
inhibitors of cAMP synthesis (SQ22536) or of PKA (H89 and PKI 6-22) but not of
irrelevant kinases (chelerythrin or KT5823) (Fig. lOA), indicating that the C5a effect is
mediated by cAMP-dependent PKA signaling. Importantly, the upregulation of nitric
oxide levels by inhibitors of cAMP or of PKA was linked to significantly reduced
intracellular survival of P. gingivalis in those same cells (Fig. lOB).

Moreover,

macrophage pretreatment with C5aRA counteracted the protective effect of C5a on P.
gingivalis intracellular viability, whereas L-NAME (nitric oxide synthesis inhibitor)

mimicked C5a and overrode the C5aRA effect (Fig. lOC). In contrast, D-NAME, an
inactive enantiomer control, had no effect in that regard (Fig. IOC). Interestingly, the
ability of inhibitors of cAMP or of PKA to reverse the immunosuppressive C5a effect
progressively declined with increasing delay of their addition to the culture system (Fig.
IOD). Therefore, P. gingivalis needs to immediately activate cAMP-dependent PKA
signaling to suppress the macrophage killing capacity, consistent with the requirement for
early availability of C5a in order to disable P. gingivalis-challenged macrophages.
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Figure 10. C5a-mediated inhibition of nitric oxide production and promotion
of P. gingivalis survival is cAMP and PKA dependent. (A, B) Mouse
macrophages were pretreated or not with SQ22536 (cAMP synthesis inhibitor),
H89 (PKA inhibitor), chelerythrin (protein kinase C inhibitor), PKI 6-22 (peptide
inhibitor ofPKA), or KT5823 (peptide inhibitor of protein kinase G), and then
infected with P. gingivalis with or without C5a. (C) Macrophages were pretreated
with L-NAME (or D-NAME), C5aRA, or both and then infected with P. gingivalis
with or without C5a. (D) Macrophages were incubated with P. gingivalis and C5a
in the absence or presence of SQ22536 or PKI 6-22, added before P. gingivalis
and C5a ("0 time delay") or with increasing delay times, as indicated.N02production (A) and viable counts of internalized bacteria (B-D) were determined at
24 hours after infection. In (D), the dashed line indicates P. gingivalis CFUs in the
absence of inhibitors [13.7 ± 2.7 (x 104) CFUs]. Results are means ±SD (n= 3)
from typical experiments performed at least twice with consistent results. *p <
0.05 and **p < 0.01 compared to corresponding controls .• p < 0.01 in C5a + Pg
with inhibitor or antagonist compared to C5a + Pg only. In (C), the inverted
triangle shows significant (P < 0.01) reversal of the C5aRA effect.

48

-------------------------------------------------------------------------------------------

In vivo exploitation of C5aR signaling for inhibition of nitric oxide and promotion of
microbial survival

To determine if C5aR signaling promotes P. gingivalis virulence also in vivo, we
investigated the pathogen's ability to survive in mice after intraperitoneal infection, in the
absence or presence of C5aRA. At 24 hours post-infection, the peritoneal lavage fluid
from C5aRA-treated mice contained significantly lower P. gingiva/is CFU compared to
control mice (>95% reduction; Fig. IIA).

Consistent with this, C5ar-l - mice were

superior to wild-type controls in controlling the P. gingivalis infection (Fig. IIA). The
wild-type control mice were additionally found to be bacteremic for P. gingivalis (4 out
of 5 mice in this group had positive blood cultures 24 hours post-infection), whereas no
bacteremia could be detected in C5ar-l - or C5aRA-treated wild-type mice, further
indicating that C5aR signaling promotes P. gingivalis virulence. Additional support that
the reduced peritoneal bacterial burden in the absence of C5aR signaling reflects
increased P. gingiva lis killing (rather than P. gingivalis escaping and taking up residence
in internal organs) was obtained by lack of P. gingiva/is CFU detection in homogenates
of several organs examined (spleen, kidney, liver, and lungs) from either C5ar-l - or wildtype mice. The ability of C5aRA-treated mice for enhanced clearance of P. gingivalis
correlated with elevated nitric oxide production (relative to control mice), whereas LNAME counteracted both effects (Fig. 11, B and C). Therefore, as shown in vitro, the in
vivo exploitation of C5aR signaling by P. gingivalis for enhanced survival involves a

nitric oxide-dependent mechanism.
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Figure 11. P. gingivalis exploits C5aR signaling to inhibit nitric oxide
production and promote its survival in vivo. (A) Wild-type (WT) mice were
intraperitoneally pre-treated with C5aRA (1 mg per kilogram body weight) or
phosphate-buffered saline (PBS), followed by intraperitoneal infection of these
mice, as well as mice deficient in C5aR (C5ar -1-), with P. gingivalis (5 x 107
CFU). Wild-type mice were intraperitoneally pre-treated or not with C5aRA,
with or without L-NAME or D-NAME (0.1 ml of 12.5 mM solution,
corresponding to 0.34 mg per mouse), followed by intraperitoneal infection with

P. gingivalis (B and C). Peritoneal fluid was harvested 24 hours after infection
and used to determine viable P. gingivalis CFU (A and C) and N02- production
(B). Data are from typical experiments performed twice yielding consistent
findings and represent means ± SD (n = 5 mice) or are shown for each individual
mouse with horizontal lines denoting mean values. *p < 0.01 compared to
controls. The inverted triangles show significant (P < 0.01) reversal of the
C5aRA effects.
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Synergistic activation of the cAMP-PKA pathway requires C5aR-TLR2 crosstalk

A systematic analysis of crosstalk in intracellular signaling pathways has revealed
that receptor-mediated elevation of intracellular Ca2+ may potentiate cAMP induction by
appropriate stimuli (36). If the synergistic effect of C5a on cAMP induction (Fig. 9E)
depends upon its Ci+-mobilizing activity, then this synergy should be inhibited by
thapsigargin, an inhibitor of the endoplasmic reticulum Ca2+-ATPase which blocks the
C5a-induced intracellular Ca2+ response (121). Indeed, macrophage pretreatment with
thapsigargin abrogated the synergistic C5a effect on P. gingivalis-induced cAMP,
whereas EGTA, which chelates extracellular Ca2+, had a relatively minimal and
statistically insignificant effect (Fig. 12A). Significant reversal of the C5a effect on
cAMP induction was also seen in cells pretreated with pertussis toxin (Fig. 12A),
suggesting GUj-coupled C5aR signaling (49).
In the absence of C5a, the ability of P. gingivalis to induce cAMP depends on its
interaction with the CXC-chemokine receptor 4 (CXCR4) (11).

We thus initially

speculated that the synergistic C5a effect on cAMP induction could involve a crosstalk
between C5aR and CXCR4. Although CXCR4 blockade by AMD3100 (at 1

~g/ml

which completely inhibits the CXCR4-P. gingivalis interaction (11)) modestly attenuated
the synergistic C5a effect on cAMP production, the synergism was still profoundly
manifested (>6-fold difference between AMD+C5a+Pg vs. AMD+Pg; Fig. 12B).
Moreover, P. gingivalis failed to elevate intracellular cAMP in CXCR4-transfected CHOKl cells, although it induced cAMP production in cells co-transfected with CXCR4 and
TLR2 (data not shown). Therefore, CXCR4 is not directly involved in cAMP induction
but cooperates in that regard with TLR2, which on its own induces a rather weak cAMP
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response (data not shown). We next showed that the synergistic C5a effect on cAMP
induction actually involves a crosstalk with TLR2.
Indeed, the ability of C5a to synergistically induce cAMP and activate PKA in P.
gingivalis-stimulated wild-type macrophages was utterly absent in similarly stimulated

Tlr2-1- macrophages, which displayed only background activity levels (Fig. 12, C and D).
However, the inherent capacity of Tlr2-1- macrophages to elevate intracellular cAMP and
activate PKA was confirmed by including a forskolin control (direct adenylate cyclase
activator) (Fig. 12, C and D). This novel concept of C5aR-TLR2 crosstalk for synergistic
cAMP-dependent PKA activation is consistent with additional findings from an in vivo
experiment.

Indeed, the PKA activity detected in freshly explanted peritoneal

macrophages from P. gingivalis-infected mice was significantly reduced by TLR2 or
C5aR deficiency, but not by TLR4 or C3aR deficiency, relative to cells from wild-type
mice (Fig. 12E).
We also showed that another synergistic interaction downstream of this receptor
crosstalk involved PKA-dependent phosphorylation of glycogen synthase
(GSK3~)

kinase-3~

on Ser9 (Fig. 12F), an event that inactivates this kinase which would otherwise

positively regulate cell activation (47).

Indeed, although C5a or P. gingivalis by

themselves only slightly increased Ser9-phosphorylation of

GSK3~,

their combination

displayed a synergistic effect which was inhibited by PKI 6-22 (but not by PD98059
control, an inhibitor of mitogen-activated protein kinase kinase) (Fig. 12F). Importantly,
the

GSK3~

inhibitor SB216763 mimicked the inhibitory C5a effect on P. gingivalis-

induced iNOS expression and nitric oxide production, as did 8-Br-cAMP (PKA agonist;
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positive control) (Fig. 120). Thus,

OSK3~

appears to regulate iNOS and nitric oxide

downstream of PKA in C5a plus P. gingivalis-challenged macrophages.
The C5aR-TLR2 crosstalk is also consistent with confocal microscopy findings
revealing for the first time co-localization of the two receptors in P. gingivalis-stimulated
macrophages (Fig. 13B), and with fluorescence resonance energy transfer (FRET)
experiments indicating that C5aR, TLR2, and P. gingivalis come into molecular
proximity (Fig. 13A).

Indeed, FRET analysis revealed significant energy transfer

between Cy3-labeled C5aR and Cy5-labeled TLR2 in P. gingivalis-stimulated but not
resting macrophages (Fig. 13A). No significant energy transfer was detected between
Cy3-labeled C5aR and Cy5-labeled TLR5 or MHC Class I (controls) under the same
conditions (Fig. 13A).

Moreover, significant energy transfer was observed between

FITC-Iabeled P. gingivalis and TRITC-Iabeled C5aR or TLR2 (but not TLR5 or MHC
Class I) (Fig. 13A).

However, unlike TLR2 which can directly be engaged by P.

gingivalis (59) (137), C5aR appeared to associate indirectly with P. gingivalis in a TLR2-

dependent way; indeed, the P. gingivalis-C5aR FRET association was abrogated in TlrTImacrophages (Fig. 13A).

Taken together, the findings firmly establish a crosstalk

between C5aR and TLR2 for synergistic induction of cAMP signaling.
FRET analysis further revealed that in P. gingivalis-challenged macrophages,
C5aR also associates with CXCR4 (Fig. 13A), suggesting co-association of all three
receptors (CXCR4, TLR2, C5aR). These interactions likely occur in lipid rafts since all
three receptors (but not TLR5 or MHC Class I) come within FRET proximity with an
established lipid raft marker (OM1 ganglioside) in P. gingivalis-stimulated macrophages,
unless the rafts are disrupted by

methyl-~-cyc1odextrin
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(data not shown). Although the

------------------------

C5aR-TLR2 crosstalk can proceed independently of CXCR4 and potently upregulates
cAMP (Fig. 12B), maximal cAMP induction requires cooperation of all three receptors
(Fig. 14).
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Figure 12. Synergistic activation of the cAMP-PKA pathway requires C5aRTLR2 crosstalk. (A-D) Macrophages pre-treated with either thapsigargin (TG),
EGTA, pertussis toxin (PTX) (A) or AMD3100 (B-D) were stimulated with P.

gingivalis with or without C5a and assayed for cAMP production (A-C) or PKA
activity (D) with or without PKI-6-22 (PKA inhibitor) and an irrelevant kinase
inhibitor (KT5823). (E) PKA activities from freshly explanted peritoneal
macro phages were determined from P. gingivalis-infected mice. (F) P. gingivalischallenged macrophages, pretreated with PKI-6-22 or PD98059, were assayed for
GSK3b Ser9-phosphorylation and total GSK3b, in the absence or presence of C5a.
(G) Macrophages stimulated with P. gingivalis with or without C5a, SB216763, or 8Br-cAMP were assayed for iNOS (4 hours) or N0 2- (24 hours). Data are means ± SD.
*p < 0.05; **p < 0.01 between the indicated groups or compared to controls (E).
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Figure 13. Lipid raft recruitment and co-Iocalizaion of C5R and TLR2
in macrophages challenged with P. gingivalis. (A) FRET between the
indicated donors and acceptors measured from the increase in donor (Cy3 or
FITC) fluorescence after acceptor (Cy5 or TRITC) photobleaching. (B)
Confocal co-localization of P. gingivalis (green), C5aR (red), and TLR2
(blue). Bottom right, merged image.
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Figure 14. TLR2 and C5aR signaling synergize to subvert macrophage
killing of P. gingivalis in a PKA-dependent fashion. P. gingivalis induces
a weak TLR2-dependent induction of cAMP production (left), whereas
CXCR4 or C5aR signaling alone fails to do so (middle). However, P.

gingivalis-induced TLR2 signaling with concomitant activation of C5aR
and, to a lesser extent, CXCR4 synergistically enhances the
immunosuppressive cAMP-PKA pathway that inactivates GSK3b and
impairs iNOS-dependent killing.
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DISCUSSION

A molecular crosstalk between the complement system and the TLRs seems
essential to appropriately coordinate the early innate response to infection (63) (165).
Here, we addressed the intriguing possibility that at least some of the complement-TLR
interplay may be instigated by pathogens, such as P. gingivalis, for promoting their
adaptive fitness. The necessity for this evasion mechanism may be related to the fact that

P. gingivalis cannot antagonize TLR2 activation at the receptor level, as it does with
TLR4 (113). Therefore, it can be stated that this pathogen has evolved a subversive
C5aR-TLR2 crosstalk mechanism for blunting the TLR2 antimicrobial response (Fig.
14), as an alternative to direct TLR2 antagonism. Notably, P. gingivalis does not rely on
immunological mechanisms for C5aR activation, since it can activate this receptor
through gingipain-mediated local generation of C5a (69). We confirmed and expanded
the biochemical demonstration of C5a generation by purified gingipains acting on
purified C5 substrate (69), by estimating that P. gingivalis generates high levels of C5a
(32.7 ± 4.3 nM) upon 30-min incubation in heat-inactivated human serum. Notably,
unlike C5a, C3a is extensively degraded and inactivated by P. gingivalis (69). Since C3a
(but not C5a) exerts direct bactericidal effects (113), C3a destruction by P. gingivalis
may serve to protect this pathogen.
The striking ability of C5a to synergize for cAMP production with P. gingivalis in
a pertussis toxin-sensitive and TLR2-dependent way could be explained as follows. The
Gi~'Y

subunits, released upon activation of the pertussis toxin-sensitive Gai subunit, can

potently regulate adenyl ate cyclase (AC) activity, either positively or negatively
depending on the enzyme isoform (107). Thus, although
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Gi~'Y

cannot stimulate AC by

themselves, they can dramatically upregulate the activity of several AC isoforms in the
presence of an appropriate stimulus.
gingivalis activation of TLR2.

regulated by

Gi~y

Such stimulus is apparently provided by P.

Importantly, the AC isoforms which are positively

are not those that are sensitive to the inhibitory action of Gai (107).

Since the ability of CSa to synergize with P. gingivalis for cAMP production is
additionally dependent on intracellular Ca2+, Gi~y may possibly mediate their stimulatory
effects on AC activity through their Ca2+-mobilizing effects.
A major mechanism underlying the regulatory effects of cAMP on cell activation
involves the ability of cAMP-dependent PKA to phosphorylate the cAMP response
element-binding protein (CREB), which effectively competes with the p6S subunit of
nuclear factor-KB for limiting amounts of common transcriptional cofactors (12S).
Besides being under nuclear factor-KB control, the iNOS is additionally regulated by
IFN-y; interestingly, however, PKA also inhibits the IFN regulatory factor-1 that is
required for the synergistic IFN-y contribution to iNOS transcription (24) (101).
Moreover, as supported by the figure 12F data, PKA can phosphorylate and inactivate
GSK3~,

thus abrogating its stimulatory effect on pro-inflammatory gene expression (47).

Since PKA activation causes greater iNOS inhibition than

GSK3~

inactivation (Fig.

12G), it is likely that PKA may inhibit iNOS also in a GSK3~-independent way (Fig. 14).
Although modest TLR-induced cAMP induction may control excessive proinflammatory signaling, sustained high levels of cAMP instigated by pathogens (and thus
out of host control) may impair host defense. P. gingivalis is the first pathogen shown to
exploit complement and TLRs to cause cAMP-dependent immune subversion in vitro and
in vivo. It should be noted, however, that the interaction of CSa with P. gingivalis-
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challenged macrophages did not induce a generalized or nonspecific macrophage
immunosuppression, since C5a actually enhanced P. gingivalis-induced interleukin-6 (IL6) production (data not shown). This sophisticated subversive crosstalk instigated by P.
gingivalis (Fig. 14) serves in lieu of "built-in" adenyl ate cyclase which is not expressed

by this bacterium, in contrast to Bordetella pertussis which disables human or mouse
phagocytes by means of its own adenylate cyclase (14).
Macrophages can interact with P. gingivalis not only in periodontal tissues but
also in the setting of systemic inflammatory diseases such as atherosclerosis (10) (114)
(160). Our previous findings that P. gingiva lis persists intracellularly in macrophages for
at least 72h (147) were confirmed by an independent group, which additionally showed
that up to 25% of the cells undergo necrosis by 72h and release cellular contents (100). It
is thus conceivable that viable P. gingivalis could be released from necrotic macrophages,
especially in the presence of C5a which dramatically promotes its intracellular
persistence.

This possibility becomes intriguing in view of epidemiological and

mechanistic links between periodontitis and atherosclerosis (10) (114).

However,

whether the documented localization of viable P. gingivalis bacteria in atherosclerotic
plaques (27) can be attributed to relocation of infected macrophages from periodontal
tissues is currently uncertain.

Nevertheless, the pathogen's capacity to exit initially

infected host cells and then enter and multiply within new hosts, including vascular cells,
has been documented (29) (156).
C5aR activation in macrophages was also shown to inhibit TLR4-induced mRNA
expression oflL-12p35, IL-12/IL-23p40, and IL-23pI9, and production oflL-12p70 and
IL-23 protein, through C5a-induced phosphatidylinositol-3 kinase and extracellular
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signal-regulated kinase 112 signaling (63) (64) (165). The physiological significance of
these C5a regulatory effects is likely to attenuate potential tissue damage mediated by
various T cell effector subsets (e.g., Th1 and Th17, regulated by IL-12 and IL-23,
respectively), as seen in various pathological inflammatory conditions (91). However,
undesirable outcomes may arise when C5a is not produced physiologically but rather
through the uncontrolled action of microbial enzymes. In this context, pathogen-induced
generation of C5a may modify TLR signaling and skew the T helper response in ways
that could interfere with protective immunity. Therefore, on the basis of our findings and
the reports on IL-12 and IL-23 regulation by C5a, it becomes evident that pathogens may
exploit TLR-C5aR crosstalk in various ways.
In summary, this work constitutes the first report of complement-TLR crosstalk
for synergistic cAMP induction which disables macrophages.

From a therapeutic

viewpoint, C5aR blockade effectively deprived this pathogen of crucial survival tactics
and may thus confer protection against periodontitis and associated systemic diseases like
atherosclerosis.

Since C5a can be generated by both complement and non-complement

C5 convertases that also include microbial enzymes (69) (112) (136), it becomes
important to identify other pathogens that exploit C5a-mediated subversive crosstalk
signaling with TLRs. This will have important implications for novel counter-strategies
to neutralize microbial virulence. Our findings further suggest that, in the course of
evolution, chronically persisting pathogens may not have simply "learned" to breach
complement and the TLRs separately, but, as hereby exemplified by P. gingivalis, to also
exploit their communication hubs.
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CHAPTER FIVE: THE C5A RECPTOR IMP AIRS IL-12-DEPENDENT
CLEARANCE OF PORPHYROMONAS GINGIVALIS AND IS REQUIRED FOR
INDUCTION OF PERIODONTAL BONE

Introduction

In addition to its role in pathogen recognition and elimination, the complement
network regulates immune and inflammatory responses through direct effects on immune
cells or via crosstalk with TLRs and other signaling pathways (130). Both complement
and TLRs are rapidly activated in response to infection and their crosstalk may serve to
coordinate the host response through synergistic or antagonistic interactions.

These

interactions may respectively enhance host defense or control it to prevent
immunopathology.

However, the propensity of complement and TLRs for

communication may be exploited by microbial pathogens to manipulate the host response
in ways that promote their adaptive fitness (52).
In this context, we have recently shown that the periodontal pathogen
Porphyromonas gingivalis induces a subversive crosstalk between the complement C5a

receptor (C5aR) and TLR2 that impairs nitric oxide-dependent intracellular killing in
macrophages (157). Interestingly, P. gingivalis can control both receptors: it can directly
engage TLR2 through cell-surface ligands (4), whereas it can activate C5aR (CD88)
through local conversion of C5 to C5a using its own enzymes (157).

Indeed, this

bacterium does not have to rely on immunological mechanisms for C5a generation, but
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rather expresses extracellular cysteine proteinases (gingipains) which function as CS
convertase-like enzymes (12S) (1S7).
CSaR activation has been also shown to downregulate TLR4-induced production
of IL-12 in vitro and in vivo (63) (8S) (16S). This effect is exerted at the transcriptional
level since CSaR signaling in macrophages inhibits TLR4-induced mRNA expression of
the IL-12p3S and IL-12/IL-23p40 subunits.

Since IL-12 is a key cytokine in Thl

differentiation and cell-mediated immunity, this CSaR-TLR4 crosstalk may represent a
regulatory mechanism to control IL-12 production and thereby prevent or attenuate
possible immunopathology (S2). However, undesirable outcomes could arise if CSa is
produced at excessively high levels, as may happen in sepsis. Under such conditions, the
crosstalk between CSa-activated CSaR and TLR4 could severely suppress IL-12 and
interfere with protective Thl immunity (S2) (63).
High levels of CSa can be generated also through the uncontrolled action of CSconvertase-like microbial enzymes like the P. gingivalis gingipains (1S7). We therefore
hypothesized that P. gingivalis may take advantage of CSa-induced signaling to suppress
biologically active IL-12 (IL-12p70). Given that IL-12p70 induces IFN-y and mediates
bacterial clearance through activated phagocytes (IS3), possible inhibition of this
cytokine by P. gingivalis through CSaR exploitation could contribute to its ability to
evade immune control. In this chapter, we show that CSa (and, to a lesser extent, its
desarginated derivative CSadeSArg) inhibits TLR2-dependent induction of IL-12p70, but
enhances induction of pro-inflammatory and bone-resorptive cytokines

(IL-I~,

IL-6, and

TNF-a), in response to P. gingivalis. These in vitro observations were confirmed by in
vivo studies, which additionally showed that CSaR-dependent inhibition of IL-12p70
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promotes the survival of this pathogen. Moreover, C5aR signaling was required for the
ability of P. gingivalis to induce periodontal bone loss in a mouse model of experimental
periodontitis. Therefore, P. gingivalis exploits C5aR to promote its adaptive fitness and
cause periodontal disease. This immune subversion mechanism has important therapeutic
implications given the current availability of safe, selective, and potent C5aR antagonists.

Results

P. gingivalis proactively and selectively inhibits IL-12p70 production via C5aR-

TLR2 crosstalk
We investigated whether C5a inhibits P. gingivalis-induced IL-12p70 in
peritoneal macrophages. E. coli LPS-stimulated macrophages were used as a control
since C5a has been shown to inhibit IL-12p70 through a C5a/C5aR-LPS/TLR4 crosstalk
(63). The host TLR response against P. gingivalis is predominantly mediated by TLR2
both in vitro and in vivo (54) (55) (11). Therefore, we additionally examined whether
possible C5a-mediated inhibition of P. gingivalis-induced IL-12p70 could involve a
C5aR-TLR2 crosstalk.

We found that the abilities of both P. gingivalis and LPS to

induce IL-12p70 production were significantly inhibited by C5a (p < 0.01; Fig. 15A).
These inhibitory effects were specifically mediated by C5aR signaling since they were
completely reversed by a specific C5aR antagonist (C5aRA) (p < 0.01; Fig. 15A).
Intriguingly, we observed that C5aR blockade significantly enhanced the
induction of IL-12p70 production, even in P. gingivalis-stimulated macrophages that
were not treated with exogenous C5a (p < 0.01; Fig. 15A). However, we did not observe
this upregulatory effect of C5aR antagonism in LPS-stimulated macrophages (Fig. 15A).
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We previously showed that P. gingivalis uses its gmglpams to generate C5a in
complement-inactivated serum (157).

Therefore, we reasoned that endogenously

generated C5a limits P. gingivalis-induced IL-12p70 production, which is thus enhanced
in the presence of C5aRA. This notion was substantiated by the finding that the isogenic
mutant KDP128, which lacks all three gingipain genes, failed to regulate IL-12p70,
unless exogenous C5a was added in the cell cultures (Fig. 15B). Indeed, C5aRA had no
effect on KDPl28-induced IL-12p70 in the absence of exogenously added C5a (Fig.
15B). The ability of P. gingivalis to induce IL-12p70 was completely abrogated in
TLR2-deficient macrophages, whereas, as expected, LPS-induced IL-12p70 was
unaffected (Fig. 15C). Taken together, these data indicate that P. gingivalis activates a
C5aR-TLR2 crosstalk which inhibits IL-12p70 production in macrophages.
The C5aR crosstalk pathways with TLR2 or TLR4 for IL-12p70 regulation appear
to be similar, since the inhibitory effects of C5a were abrogated by treatment with the
MEK1I2-specific inhibitor U0126 but not by the PI3K inhibitor wortmannin (p < 0.01;
Fig. 15D). This implicates the MEK-ERKI/2 pathway in C5aR-mediated regulation of
both TLR2- and TLR4-induced IL-12p70.

On the other hand, the PI3K pathway is

minimally involved, if at all (63). The C5aR-dependent inhibition of IL-12p70 in P.
gingivalis-stimulated macrophages was selective for this cytokine, since other proinflammatory cytokines (IL-6 and TNF-a) were augmented (p < 0.01; Fig. IE).

In

conclusion, P. gingivalis proactively and selectively inhibits IL-12p70 production by
activating a C5aR-TLR2 crosstalk without requirement for immunological mechanisms
of complement activation.
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Figure 15: C5aR signaling inhibits TLR2-dependent IL-12p70 induction in
P. gingivalis-activated macro phages. IFN-y primed wild-type (A-D) or

TLR2-deficient (C) mouse peritoneal macrophages were stimulated with
medium, P. gingivalis, or E. coli LPS. Panel B includes the use of an isogenic
mutant (KDP128) which is deficient in all three gingipain genes. Macrophages
were pre-treated with C5aRA (A-B), U0126 or wortmannin (D) prior to
challenge with C5a, P. gingivalis, or Ec-LPS.

Culture supernatants were

assayed for induction of the indicated cytokines after 24h of incubation. Data
are means ± SD (n = 3 sets of macrophages). Asterisks show statistically
significant (p < 0.01) inhibition (A-D; IL-12p70) or enhancement (E; IL-6 and
TNF-a) of cytokine production, whereas black circles indicate statistically
significant (D < 0.01) reversal of these modulatorv effects.
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C5aR signaling in vivo differentially regulates P. gingivalis-induced cytokine
responses
We next investigated the biological significance of the C5aR-mediated inhibition
of IL-12p70 production. First, it was essential to determine whether C5aR signaling can
regulate P. gingivalis-induced IL-12p70 production also in vivo. For this purpose, wildtype mice were i.p. administered C5aRA followed by i.p. challenge with P. gingivalis.
Mice deficient in C5aR or TLR2 were similarly challenged with P. gingivalis, and all
mice were sampled 5h post-infection by peritoneal lavage. In addition to IL-12p70, we
determined production ofIFN-y (which is positively regulated by IL-12p70 (153)), IL-23
(an IL-12 family cytokine which shares a common IL-12/IL-23p40 subunit with IL12p70 (119), as well as pro-inflammatory cytokines that have been implicated in
inflammatory bone resorption in periodontitis

(IL-l~,

IL-6, and TNF-a) (43). C5aRA-

treated wild-type mice and C5aR-deficient mice elicited significantly higher levels of IL12p70, IFN-y, and IL-23 compared to PBS-treated wild-type controls (p < 0.01-0.05; Fig.
16). In contrast, the induction of IL-l~, IL-6, and TNF-a production was inhibited by
C5aR blockade or C5aR deficiency (p < 0.01; Fig. 2). On the other hand, the induction
of all tested cytokines was abrogated in TLR2-deficient mice (p < 0.01; Fig. 2). These
data confirm that C5aR signaling in vivo selectively inhibits the ability of P. gingivalis to
induce TLR2-dependent IL-12 family cytokines (IL-12p70 and IL-23). Additionally, the
observed downregulation of IFN-y is most likely secondary to inhibition of IL-12p70
production. On the other hand, maximal induction of IL-l~, IL-6, and TNF -a requires
intact signaling by both C5aR and TLR2.
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Figure 16. C5aR signaling regulates P. gingivalis-induced and TLR2dependent cytokine production in vivo. 10-12 week-old wild-type (WT)
mice, which were pretreated or not with C5aRA (i.p.; 25 Ilglmouse), as
well as mice deficient in C5aR (e5ar-I -) or TLR2 (TlrT I-), were i.p.
infected with P. gingivalis (5x10 7 CFU). Peritoneal lavage was performed
5h post-infection and the peritoneal fluid was used to measure the levels of
the indicated cytokines.

Mice not infected with P. gingivalis had

undetectable levels of the cytokines investigated. Data are means ± SD (n =
5 mice). *,p < 0.01 and ** , p < 0.01 vs. WT+PBS control.
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C5aR-mediated inhibition of IL-12p70 promotes P. gingivalis survival in vivo

Whether the C5aR-mediated inhibitory effect on IL-12p70 production (Fig. 16) is
exploited by P. gingiva lis was addressed in subsequent experiments. Wild-type mice
were i.p. treated with C5aRA (or PBS control) and infected with P. gingivalis by the
same route. The C5aRA-treated mice comprised several groups, including mice given
anti-IL-12 IgG, anti-IL-23p19 IgG, or non-immune IgG control. Treatment with anti-IL23p19 was included because the anti-IL-12 Ab reacts with both IL-12p70 subunits, p35
and p40, the latter of which is shared by the heterodimeric IL-23 (IL-12/IL-23p40 and IL23p19 (119)). Thus, the experiment was designed in a way that would allow specific
implication of IL-12p70 or both IL-12p70 and IL-23 in P. gingivalis immune clearance.
At 24h post-infection, the peritoneal lavage fluid from C5aRA-treated mice contained
about 2 lOglO units less P. gingiva lis CFU compared to mice pretreated with PBS control
(p < 0.01; Fig. 17A). However, the enhanced ability ofC5aRA-treated mice to clear P.
gingivalis was significantly (p < 0.01) counteracted by anti-IL-12 treatment, though not

by anti-IL-23p19 or non-immune IgG (Fig. 17A). Viable P. gingivalis CFU counts were
not detected in the blood or in homogenates of several organs examined (spleen, kidney,
liver, and lungs) from any of the mouse groups. Taken together with the Fig. 16 findings,
these data show that C5aR signaling inhibits IL-12p70 production and this inhibitory
effect is exploited by P. gingivalis to resist immune clearance. This conclusion was
further substantiated by similar findings from a related experiment in which C5aRAtreated mice were replaced by C5aR-deficient mice (Fig. 17B).
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Figure 17. Inhibition of CSaR signaling promotes the in vivo clearance of
P. gingivalis by augmenting IL-12. (A) Wild-type mice were pre-treated or

not with C5aRA (i.p.; 25 flg/mouse), in the presence or absence of goat
polyclonal anti-mouse IL-12 IgG, anti-mouse IL-23p19 IgG, or equal amount
of non-immune IgG (i.p.; 0.1 mg/mouse). The mice were then infected i.p.
with P. gingiva lis (5x10 7 CPU). (B) Similar experiment in which C5aRAtreated mice were replaced by C5aR-deficient (C5ar-/-) mice. Peritoneal
lavage was performed 24h post-infection and the peritoneal fluid was used to
determine viable P. gingivalis CPU counts. Data are shown for each
individual mouse with horizontal lines indicating mean values. *, p < 0.01 vs.
controls. The inverted triangles indicate significant (p < 0.01) reversal of the
effects ofC5aRA or C5aR deficiency by anti-IL-12.
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Comparison of C5a and C5adesArg in regulating IL-12p70 and other macrophage
activities
The peritoneal fluid of P. gingivalis-infected mice from the above described
experiments was also assayed by mouse CSa ELISA. CSa was detected at 2304 ± S27
pg/ml (n = S mice) and 1629 ± 378 pg/ml (n = S mice) at, respectively, Sh and 24h postinfection. CSa is relatively unstable in biological fluids and is rapidly converted to its
desarginated form (CSadeSArg).

In fact, a large part of detected CSa may represent

CSadesArg since the capturing antibody used in the sandwich ELISA (BD Pharmingen)
recognizes a neoepitope exposed in both CSa and CSadesArg (though not in intact CS).
CSadesArg does not have anaphylactic action but retains a number of other biological
activities (97) (102) (107). We thus investigated whether it shares the capacity of CSa to
regulate IL-12p70. We found that CSadesArg can also inhibit P. gingivalis-induced IL12p70 production, though not as strongly as CSa.

Specifically, CSadesArg mediated

significant (p < O.OS) inhibition of IL-12p70 at SO nM but not at 10 nM, at which
concentration CSa was already effective (Fig. 18A). However, the increased stability and
thus higher prevalence of CSadesArg compared to intact CSa suggests a possible significant
role for the desarginated molecule in IL-12p70 regulation.
Although CSadesArg binds also to the CSa-like receptor-2 (CSL2) with high affinity
(120) (130), its observed modulatory effect on IL-12p70 production was likely mediated
via the CSaR (CD88).

In this regard, CSaRA by itself caused full reversal of the

inhibitory effect of CSadesArg, whereas a dual CSaRlCSa-like receptor-2 antagonist (A8t.7173)

(120) (133) had a comparable effect (Fig. 18B). In contrast, the C3aR antagonist
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SB2901S7 (control) did not influence the ability of CSadesArg to inhibit induction of IL12p70 by P. gingivalis (Fig. 18B).
We previously implicated CSa in synergistic interactions with P. gingivalis that
elevate cAMP in macrophages, leading to inhibition of nitric oxide production and of
intracellular killing (1S7). We investigated whether these evasion mechanisms can also
be activated by CSadesArg. Side-by-side comparison revealed no significant differences
between CSa and CSadesArg when tested at SO nM in elevating cAMP, inhibiting nitric
oxide, and promoting its intracellular survival (Fig. 18, C-E).

However, when the

compounds were tested at 10 nM, CSa exhibited stronger effects than CSadesArg (Fig.18,
C-E).

In view of the strict dependence of CSa on intracellular Ca2+ mobilization to

synergistically elevate cAMP (IS7), we hypothesized that CSadesArg could similarly
induce intracellular Ca2+ responses.

Indeed, at SO nM, CSa and CSadesArg induced

comparable intracellular Ca2+ mobilization in macrophages (Fig. 19A), whereas only CSa
was active in that regard in neutrophils (Fig. 19B). Taken together, the data from Figs. 18
and 19 indicate that P. gingivalis can exploit CSa even after its conversion to CSadesArg,
thereby undermining macrophage defense functions (induction ofIL-12p70, activation of
intracellular killing).
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Figure 18.

Comparative modulatory effects of CSa and CSadesArg on IL-12p70

production and antimicrobial activities in P. gingivalis-challenged macrophages.
Groups of mouse peritoneal macrophages were incubated with P. gingivalis

in the

absence or presence ofC5a or C5adesArg (at 10 or 50 nM) and assayed for (A) induction of
IL-12p70 (after 24h), (C) generation of cAMP (lh), (D) N02- (24h), and (E) viable counts
(CFU) of internalized bacteria (24h). In panel B, the macrophages were pre-treated with
C5aRA, the dual C5aRlC5a-like receptor-2 antagonist A8~71-73, or the C3aR antagonist
SB290157 to determine the receptor by which C5adesArg (50 nM) inhibits IL-12p70
production. Data are means ± SD (n = 3 sets of macro phages). *, p < 0.05 and ** , p <
0.01 compared to no C5a or C5adesArg (0 nM). In B, black circles indicate statistically
significant (p < 0.01) reversal of the inhibitory effect of C5adesArg. In panels C-E, no
significant differences were found between C5a and C5adeSArg when tested at 50 nM.
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Figure 19. Comparison of C5a and C5adesArg in intracellular Ca2+
mobilization.

Mouse peritoneal macrophages (A) or neutrophils (B)

were loaded with the ratiometric calcium indicator Indo-! AM and
stimulated with C5a or C5adesArg at the indicated concentrations (lower
concentrations were used for neutrophils since they are more sensitive to
C5a than macrophages (49)). Ca2+ mobilization was measured in a
spectrofluorometer and the traces are representative of three experiments.
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C5aR mediates periodontal bone loss

The involvement of CSaR signaling in P. gingiva/is immune evasion and in the
induction of pro-inflammatory cytokines (Figs. lS-18), such as

IL-1~,

IL-6, and TNF-a

that mediate periodontal bone resorption (43), suggested that CSaR may play an
important role in P. gingivalis-induced periodontitis.

Indeed, P. gingiva lis failed to

induce significant periodontal bone loss in CSaR-deficient BALB/c or CS7BLl6 mice, in
stark contrast to corresponding wild-type mice which developed significant bone loss
relative to sham-infected controls (p < 0.01; Fig. 20 A, B, and E). TLR2 participates in
crosstalk interactions with CSaR that promote mechanisms of P. gingiva lis immune
evasion (1S7) and induce production of bone-resorptive cytokines (Fig. 16). Sensibly,
therefore, TLR2-deficient BALB/c mice were similarly shown to be resistant to P.
gingivalis-induced periodontal bone loss (Fig. 20 C and E).

Mice used for P. gingivalis-induced periodontitis studies are usually 8-12 weekold and sham-infected controls do not develop appreciable bone loss (44). However,
aging mice, like aging humans, gradually develop naturally-occurring inflammatory
periodontal bone loss (due to chronic exposure to indigenous periodontal bacteria), which
becomes quite dramatic after 9 months of age (Sl) (93). To determine the role of CSaR in
the age-associated periodontitis model, we raised CSaR-deficient BALB/c mice and wildtype controls until the age of 16 months. We found that old CSaR-deficient mice are
significantly protected against age-associated periodontitis relative to similarly aged
wild-type controls (p < 0.01; Fig. 20D). Therefore, CSaR is involved in chronic, ageassociated periodontal bone loss. However, it is currently uncertain whether CSaR is
exploited by mouse periodontal bacteria as shown for P. gingivalis.
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Figure 20. C5aR and TLR2 deficiencies protect against periodontal bone loss.
Mice deficient in C5aR (C5ar- I-) (A, BALB/c; B, C57BLl6) or TLR2 (Tlr2- 1-) (C;
BALB/c) and appropriate wild-type controls were orally infected or not with P.
gingivalis and assessed for induction of periodontal bone loss six weeks later. Mice

used in these experiments were 10-12 week-old. (D) Induction of naturally occurring
periodontal bone loss in 16-month-old wild-type or C5ar-l - BALB/c mice relative to
their young counterparts (:s 12 weeks of age).

(E) Representative images of P.

gingivalis-induced bone loss under wild-type or C5aR- or TLR2-deficient conditions:

P. gingivalis-infected C5ar-l - or Tlr2-1- mice display considerably smaller CEJ-ABC
distances (yellow arrows) compared to infected wild-type mice, but quite comparable
to those of sham-infected wild-type mice. Data are means ± SD (n = 5 mice). *, p <
0.01 compared to corresponding sham-infected controls (A and B) or young
counterparts (C).
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Discussion

Clinical and histological observations implicate complement in periodontal
inflammation and pathogenesis, although the precise mechanisms or pathways involved
have remained largely undefined (48). However, our findings clearly implicate the C5aC5aR axis in periodontal tissue destruction and immune evasion by periodontal bacteria.
Our present data suggest that P. gingivalis may exploit C5aR to promote its
adaptive fitness in diverse ways. On the one hand, C5aR signaling inhibits TLR2dependent IL-12p70 induction and interferes with immune clearance of P. gingivalis. On
the other hand, the P. gingivalis-instigated C5aR-TLR2 crosstalk leads to enhanced
production of other pro-inflammatory cytokines

(lL-l~,

IL-6, and TNF-a). Therefore,

this pathogen does not appear to cause a generalized immunosuppression but, rather, has
evolved the ability to selectively target pathways that could result in its elimination.
Consequently, P. gingivalis is an asaccharolytic organism with a strict requirement for
peptides and hemin, and thus depends on the continuous flow of inflammatory serum
exudate (gingival crevicular fluid) to obtain these essential nutrients and survive in its
periodontal niche (34).

In fact, non-selective immunosuppression would not be

advantageous for P. gingiva/is; whereas such strategy would certainly afford protection
against host immunity; however, P. gingiva lis would likely be condemned to starvation..
Therefore, the proactive release of C5a by P. gingivalis and the ensuing C5a-induced
inflammation (increased vascular permeability and pro-inflammatory synergy with TLRs)
can contribute to nutrient procurement. Moreover, the ability of P. gingivalis to induce
C5aR-dependent periodontal bone loss expands the useful space for increased niche for
the pathogen.
77

On the basis of the above discussion, it becomes apparent that P. gingiva lis uses a
quite antithetical strategy relative to Staphylococcus aureus which promotes its survival
by actually blocking CSa binding and CSaR activation, via a secreted protein known as
CHIPS (chemotaxis inhibitory protein of S. aureus) (2S). This mechanism inhibits CSainduced inflammation and phagocytic cell chemotaxis and protects S. aureus from
neutrophils and macrophages (2S). On the other hand, the protozoan parasite Leishmania
major also exploits CSaR for evading host immunity, which is restored in CSaR-deficient

mice that consequently do not develop necrotizing dermal lesions as wild-type animals do
(63). However, unlike P. gingivalis, L. major has to rely on CSa generation by the
physiological complement cascade in order to exploit CSaR.
P. gingivalis-induced inflammation via the CSaR-TLR2 crosstalk may have

important implications from a clinical perspective, since it is likely to cause collateral
tissue damage (inflammatory periodontal bone destruction). This notion is supported by
our findings that mice deficient in CSaR or TLR2 are both resistant to P. gingivalisinduced periodontitis. The fact that induction of bone loss is essentially prevented in the
absence of either CSaR or TLR2 signaling, argues against the possibility that CSaR and
TLR2 contribute to periodontal pathogenesis through independent effector mechanisms.
In this regard, both receptors are under P. gingivalis control and are induced to crosstalk,
while in physical proximity (IS7), cooperatively leading to immune evasion and
induction of inflammatory/bone-resorptive cytokines.
Both the CSa and C3a anaphylatoxins are readily metabolized in serum and lose
their C-terminal arginine due to carboxypeptidase activity (107).

The resulting C3a

fragment (C3adesArg) is biologically inert in terms of C3a receptor-dependent functions,
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but retains antimicrobial activity which is exerted independently of the receptor (114).
On the other hand, C5adesArg can still bind C5aR, albeit with a lower affinity and a
different mode of interaction relative to intact C5a (19) (107). Although C5adesArg is
devoid of C5a spasmogenic (anaphylactic) activity, it retains other C5a activities to
varying degrees depending on function and cell type involved.

For example,

monocytes/macrophages, but not neutrophils, do not appear to distinguish between C5a
and C5adesArg in terms of induction of chemotaxis or lysosomal enzyme release (13) (97)
(102). Our findings that C5adesArg retains the ability to inhibit P. gingivalis-induced IL12p70 and nitric oxide production has important implications: being considerably more
stable than C5a (107), C5adesArg may provide a persisting stimulus for sustained
manipulation of the antimicrobial response and destructive inflammation, properties that
characterize chronic conditions like periodontitis. Intriguingly, whereas P. gingiva lis
attacks C5 and generates biologically active C5a1C5adesArg, it extensively degrades C3
and C3a which thus do not retain biological activity (161). Since C3a (but not C5a)
exerts direct antimicrobial effects and readily kills both gram-negative and gram-positive
bacteria (114), it is possible that degradation and inactivation of C3a by P. gingivalis may
serve to protect this pathogen
The data from this study collectively suggest that P. gingivalis has evolved to not
only endure the host response (by selectively suppressing critical 'killing' pathways, such
as IL-12-dependent clearance), but also to benefit from the inflammatory response, while
at the same time contributing to periodontal pathogenesis. The ability of P. gingivalis to
inhibit innate immune functions via C5aR exploitation may also allow bystander bacteria,
i.e., co-habiting the same niche, to evade immune control. In this context, P. gingivalis is
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thought of as a keystone periodontal species that could promote the survival and
virulence of the entire microbial community (20) (22) (49) (82).
In addition to being a prevalent and costly chronic condition that destroys toothsupporting tissues, severe periodontitis exerts a systemic impact on health and the
patients run increased risk for diseases such as atherosclerosis, diabetes, and perhaps
rheumatoid arthritis (26) (30) (123) (151). Therefore, it becomes important to identify
promising therapeutics for the treatment of this oral disease. Since C5aR- or TLR2deficient mice are both resistant to periodontal bone loss, at least in principle,
pharmacological blockade of either C5aR or TLR2 could inhibit periodontitis. However,
the availability of highly effective and safe C5aR antagonists, some of which have
completed phase II trials (for rheumatoid arthritis and psoriasis) (131) (155), and the
relative paucity of effective TLR2 antagonists, suggest that C5aR is a preferential and
promising target of local therapeutic intervention to treat human periodontitis. From a
mechanistic viewpoint, C5aR blockade may counteract the ability of periodontal bacteria
to evade critical antimicrobial responses or to stimulate non-resolving/destructive
inflammation, and thus should be capable of both controlling the infection and inhibiting
periodontal bone loss.
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